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Cell-cell communication is essential for proper development and homeostasis, 
the dysregulation of which can manifest in developmental defects and/or cancer. 
The Notch signaling pathway is an evolutionarily conserved pathway that has 
been implicated in many aspects of these processes. The adrenal glands are 
endocrine organs that mediate the mammalian stress response and are 
comprised of the embryological and functionally distinct cortex, which secretes 
steroid hormones, and medulla, which secretes catecholamine hormones. 
Benign tumors of the adrenal cortex, adrenocortical adenomas (ACA), are 
common while adrenocortical carcinomas (ACC) present at much lower 
frequency but with an extremely poor prognosis. The Notch ligand Jag1 
is upregulated in ACCs compared to ACAs and normal adrenals concomitant 
with upregulations of Notch receptors and target genes. The expression of Jag1 
correlates with markers of proliferation and with late stage, aggressive ACC. 
Upregulated Jag1 mediates a non-cell autonomous effect on cell proliferation 
through the activation of canonical Notch signaling. In contrast, Notch signaling 
has no apparent role in the normal adrenal cortex.  On the contrary, Notch 
ligands, receptors, and target genes are expressed in chromaffin cells of the 
adrenal medulla. Inhibition of canonical Notch signaling in chromaffin cells results 
in an upregulation of catecholamine-synthesizing enzyme TH while constitutive 
activation of Notch signaling reduces the expression of the epinehprine-
synthesizing enzyme PNMT in chromaffin cells. This thesis interrogates the 
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contrasting roles of Notch signaling in the molecular biology of the pathogenic 
adrenal cortex and normal adrenal medulla. 
 
  1 
Chapter 1:  Introduction* 
Introduction to Notch Signaling 
 A central facet to the regulation of cell biology during development and 
homeostasis is the receipt and transmission of molecular signals. For example, in 
adult tissue homeostasis, a common stem/progenitor cell must receive signals to 
direct it towards a particular cell lineage, instruct it to proliferate and expand or to 
maintain a quiescent state [1, 2]. In development, it is essential for the 
appropriate transcriptional program to be activated in order for specification of 
cell fate.   Often times, inappropriate cell signaling results in a disease state such 
as a developmental syndrome or cancer [1, 2]. Of the myriad signaling pathways, 
the highly conserved Notch pathway is a crucial player in many of these 
processes and in a wide range of tissue types.  
Notch is unique amongst signaling pathways in several respects 
(Reviewed in [3-6]). First, the core signaling components are transmembrane 
proteins that must physically interact and, as a consequence, canonical Notch 
signaling requires direct cell-cell contact. Second, generation of the active 






cleavage of the intracellular domain of the Notch receptor itself. Finally, 
despite a robust activation in numerous systems, there is no amplification of the 
active signaling molecule. These features allow for an incredible fine-tuning in 
signaling specificity and as such, the function of Notch in a particular system is 
highly context-dependent. Nevertheless, much has been learned about the 
activation and regulation of the core Notch pathway and its function in 
development, homeostasis, and disease. 
Canonical Notch signaling is initiated though receptor-ligand interaction 
that requires direct contact between adjacent cells and culminates in the release 
of the active signaling molecule, the cleaved Notch intracellular domain (NICD) 
(Fig 1). Notch receptors are large single-pass type I transmembrane that are 
highly conserved amongst vertebrates. One receptor gene has been identified in 
the fly Drosophila melanogaster, two in the worm Caenorhabditis elegans, and 
four receptors (Notch1-4) have been identified in mice and humans [4]. Notch 
receptors are composed of several functional domains but can be grossly divided 
into two regions: the Notch extracellular domain (NECD) and the Notch 
transmembrane/intracellular domain (NTMICD) (Fig 1.1A). The NECD contains 
about 29-36 epidermal growth factor (EGF)-like domains that can bind calcium 
ions and are believed to mediate interaction with Notch ligands [7-9]. Subsequent 
to the EGF repeats of the NECD is a critical region known as the negative 
regulatory region (NRR), an unstructured loop composed of three cysteine-rich 
LIN12-Notch repeats (LNR) and part of the heterodimerization (HD) domain, 
which may serve to repress Notch receptor activation in the absence of ligands [3, 
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10]. During its transit through the secretory pathway, the full length Notch 
receptor is cleaved by Furin-like convertase at the S1 site within the HD domain 
[11]. The N- and C- terminal regions of the NTMICD and NECD respectively are 
associated extracellularly though non-covalent interactions. A single 
transmembrane (TM) domain adjacent to the HD domain of the NTMICD lodges 
the Notch receptor within the membrane. Following the TM domain and located 
intracellularly are the RBPjκ association module (RAM), which is required for 
interaction with the Notch transcriptional machinery, a nuclear localization signal, 
a seven ankyrin repeats (ANK) domain, a second nuclear localization signal, a 
transactivation domain (TAD) and a proline/glutamic acid/serine/threonine-rich 
(PEST) domain, which contains degradation signals responsible for regulation of 
NICD stability. 
Notch ligands are also large single-pass type I transmembrane proteins. 
While a large number of proteins are emerging as potential Notch ligands, the 
Delta/Serrate family has been the best characterized in the activation of Notch 
signaling [12] (Fig 1.1B). Within the large extracellular domain of these Notch 
ligands are a N-terminal Delta/Serrate/Lag-2 (DSL) motif, special EGF repeats 
known as Delta and OSM-11-like protein (DOS) domain, and tandem EGF-like 
repeats. The DSL and DOS domains have been shown to be required for binding 
to Notch receptors [3, 12]. In mice, DSL containing ligands can be further 
subdivided into two classes that lack a cysteine-rich (CR) domain and include 
Delta-like (DLL) 1, 3 and 4, or posses a CR domain and include Jagged1/2 
(JAG1/2).   
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Upon ligand-receptor interaction, a series of endocytic and cleavage 
events occur that eventually results in the release of the NICD from the Notch 
receptor (Fig 1.1C). Ligand-receptor binding results in exposure and cleavage of 
the S2 site within the HD domain by ADAM metalloproteases. This step is of 
crucial importance to the regulation of Notch activity but the precise mechanism 
is unclear. It may involve endocytosis of the ligand/receptor complex, which 
generates a mechanical force that results in a conformational change of the 
NRR[13]. S2 cleavage results in an intermediate state containing the remaining 
membrane-tethered portion of the Notch receptor, called the Notch extracellular 
truncation (NEXT). Two additional cleavage sites within the TM domain, S3/4, 
are mediated by γ -secretase, a multiprotein complex composed of presenilin, 
nicastrin, APH1, and PEN2 [14]. This results in the release of the NICD which 
translocates to the nucleus and binds to the transcriptional repressor CSL 
(CBF1/RBPjk in mice, Su(H) in flys, and Lag-1 in worms) [15]. CSL is 
constitutively bound to Notch target genes and recruits co-repressors in the 
absence of the NICD. Upon NICD binding to CSL, the essential Notch 
transcriptional co-activator Mastermind (Mam), or Mastermind-like (Maml) in mice, 
is recruited to CSL to form a ternary complex which is required for induction of 
transcription. The most common Notch target genes include the Hairy-enhancer 
of-split (HES) family of bHLH transcription factors, such as Hes1, Hes5, and 
Hey1. Interestingly, no signal amplification occurs in Notch signaling and the 
Notch receptor cannot be used for additional signaling events. Therefore, despite 
the relative simplicity of the core Notch pathway, the regulation of Notch 
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activation is complex and involves ligand/receptor localization, post-translational 
modifications such as glycosylation [16, 17], trafficking and endocytosis [18, 19], 
and other molecular events [3, 4].   
 
Notch signaling in Development and Disease 
 The fine regulation of Notch signaling and its high degree of conservation 
amongst numerous phyla suggest its importance in a variety of developmental 
processes [6]. Indeed, numerous genetic syndromes in humans have been linked 
to mutations in Notch alleles (reviewed in [20]). For example, JAG1 mutations 
have been described as causative of Alagille syndrome, an autosomal-dominant 
disorder characterized by developmental defects in the liver, heart, skeleton, and 
face [21, 22]. JAG1 is widely expressed in these tissues during development of 
human embryos [23, 24]. However, the precise function of Notch signaling in 
development is highly context dependent and appears to vary from organ to 
organ. For example, in the intestine, Notch signaling seems to be essential for 
maintenance of the pluripotency of stems cells located in the crypts of intestinal 
villi [25, 26]. In contrast, in the hematopoietic system, Notch signaling does not 
be appeared to be required for the maintenance of pluripotency of hematopoietic 
stem cells but is required at several steps in T-cell development [27-29]. 
Furthermore, the importance of Notch signaling in numerous other systems has 
been described (see reviews: in vasculature [30], in heart [31], in lungs [32], in 
central nervous system [33]).  
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 Dysregulation of Notch signaling has been implicated in carcinogenesis of 
a variety of organ systems but as in development, its specific role is context 
dependent; in some instances acting as a tumor suppressor and other as an 
oncogene (Reviewed in [6, 34-36]). In contrast to its function in development, the 
Notch ligand JAG1 has been shown to be upregulated in a variety of cancers 
such as intestinal tumors [37], hepatocellular carcinoma [38], gastric cancer [39], 
and colorectal cancer [40, 41]. Furthermore, the upregulation of JAG1 in breast 
and prostate cancers has been implicated in activation of the cell cycle [42, 43], 
metastasis [44, 45], and correlated to poor prognosis [45-48]. Similar to the 
duality of JAG1 in development and disease, activating mutations in the Notch1 
receptor has been identified in T-acute lymphoblastic leukemia (T-ALL) and 
these mutations are believed to be causative in that disease [49, 50]. However, 
Notch may function as potential tumor suppressor in some systems. Indeed, 
activation of Notch1 signaling has been shown to induce cell cycle arrest in 
hepatocellular carcinoma [51], small cell lung cancer [52], and medullary thyroid 
cancer cells [53]. In the mouse, a tissue-specific loss of Notch1 in the epidermis 
results in hyperplasia followed by eventual tumor formation suggesting that Notch 
acts as a tumor suppressor in the skin [54]. Despite its significance in numerous 





Basic Biology of the Adrenal Cortex 
 The coordination of the mammalian stress response is mediated by the 
adrenal gland, an endocrine organ composed of two embryologically and 
functionally discrete regions: the adrenal cortex and the adrenal medulla (Fig 
1.2). The adrenal cortex is of mesodermal lineage and secretes steroid 
hormones while the adrenal medulla is derived from the neuroectoderm and 
secretes catecholamines [55]. Since the adrenal cortex and medulla are 
considered as separate organs, the function, development, and cancers derived 
from each will be discussed separately. 
 The outer adrenal cortex is responsible for steroid hormone output. The 
middle zone of the cortex, the Zona Fasiculata (ZF), is a component of the 
Hypothalamic-pitiuitary-adrenal (HPA) axis, an endocrine system regulating 
secretion of the glucocorticoid steroid hormone cortisol (corticosterone in mice) 
(Fig 1.2A) [56]. Coricotropin realeasing factor (CRF) is released from the 
hypothalamus and acts on corticotropes of the anterior pituitary gland in order to 
stimulate release of adrenocorticotropic hormone (ACTH), a peptide hormone 
derived from the processing of the proopiomelanocortin (POMC) peptide. ACTH 
travels through the blood stream to bind the G-protein coupled receptor 
melanocortin receptor 2 (MC2R) on the surface of the ZF adrenocortical cell 
where it induces of a signal transduction cascade that culminates in secretion of 
cortisol, a steroid hormone involved in glucose utilization and energy 
homeostasis. Cortisol acts in a negative-feedback loop to regulate the activity of 
the HPA axis in order to modulate the release of cortisol. Cortisol is secreted 
  8 
from the ZF, the middle zone of the three functional zones of the adrenal cortex 
(Fig 1.2B). The outer zone, the Zona Glomerulosa (ZG), secretes aldosterone, a 
steroid hormone involved in sodium retention under regulation of 
Renin/Angiotensin system. The inner zone, the Zona Reticularis, which is not 
present in mice, secretes sex steroid precursors such as Dehydroepiandosterone 
(DHEA) and DHEA-sulfate (DHEA-S).  
 
Development of the Adrenal Cortex 
 Formation of the adrenal gland occurs in several distinct developmental 
events and is uniquely dependent on the nuclear receptor NR5a1 (Steroidogenic 
factor 1, Sf1) [55, 57, 58] (Fig 1.3). Indeed, the lack of formation of the adrenal 
cortex in Sf1 knockout mice underscores the requirement of Sf1 expression for 
adrenocortical development and function [59]. During the 4th week of gestation in 
humans (E9.0 in mice), proliferation of mesoderm-derived cells of the coelomic 
epithelia and underlying mesonephros results in coalescence of the 
adrenogonadal primordium (AGP), defined by expression of Sf1 [60, 61].  At the 
8th week of gestation in humans (E10.5 in mice), the bipotential AGP separates 
into discrete adrenal primordia (fetal adrenal zone) and gonadal primordial [58, 
60]. The segregation of discrete adrenal primordia from the AGP is molecularly 
defined by a Wilm’s tumor 1 (Wt1) and Cited2-mediated upregulation of Sf1 
expression [62].  Once separated from the AGP, the adrenal primordia activate 
Sf1 expression through an entirely different mechanism – the recruitment of the 
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homeobox protein PKNOX1 (Prep1), homeobox gene 9b (Hox) and pre B-cell 
leukemia transcription factor 1 (Pbx1) to a fetal adrenal-specific Sf1 enhancer 
(FAdE) [63].  FAdE-dependent expression of Sf1 in the adrenal primordia is 
maintained over time through autoregulation by Sf1 itself. Proliferation of the fetal 
adrenal cortex cells is under the control of fetal pituitary-derived ACTH [64]. 
However, Insulin-like growth factor 2 (IGF2) is expressed throughout the fetal 
adrenal cortex and several studies have suggested ACTH mediates some of its 
effects on proliferation through IGF2 action [65-67]. 
 Concurrent with activation of FAdE-driven Sf1 expression at embryonic 
day E11.5-12.5 in mice (equivalent to 8-9th week of gestation in humans), neural-
crest-derived chromaffin progenitor cells migrate into the central fetal gland and 
form the adrenal medulla followed by the coalescence of the mesenchymal 
capsule around fetal adrenal [55, 68]. Before encapsulation is complete, the 
development of the definitive cortex (definitive zone or adult cortex) is initiated 
between the capsule and the fetal zone.   While the fetal cortex ultimately 
regresses in all species, the timing of regression is species-specific; in humans 
the fetal zone regression occurs at birth while in mice the zone persists until 
puberty in males and the first pregnancy in females [56].  In humans, functional 
zonation of the adult cortex into unique concentric steroidogenic regions initiates 





Adrenocortical Tumors (ACT) are extremely common neoplasms, the vast 
majority being benign adrenocortical adenomas (ACA) that occur in as many as 
4-7% of the population whereas adrenocortical carcinomas (ACC) are extremely 
rare (~0.5-2 cases/million) accounting for 0.2% of cancer deaths annually [70-74] 
(Fig 1.4). ACC is typically an aggressive neoplasm with many patients presenting 
with metastases upon diagnosis [70, 71]. Due to difficulty of early detection and 
lack of effective treatments for advanced-stage ACC, the prognosis of ACC is 
tragically unfortunate with the average survival for surgically unresectable tumors 
at 12-months and the overall 5 year survival is historically less than 10% [75, 76]. 
The molecular pathogenesis is still unclear but numerous recent insights have 
revealed several critical factors and signaling pathways. 
Together with the characterization of the genetic mutations in family 
cancer syndromes in which ACC occurs, the expression analyses of sporadic 
ACC have been extremely informative in identifying common genetic changes 
within ACC [77].  Beckwith-Wiedemann syndrome (BWS) is a genetic disease 
that increases susceptibly to a wide range of childhood tumors including ACC, 
albeit infrequently [78, 79]. BWS has been mapped to numerous genetic 
alterations of the 11p15 locus, which encodes IGF2 [79-81]. IGF2 is maternally 
imprinted and thus expression is limited to the paternal allele. Loss of imprinting 
of the IGF2 locus and resultant upregulation of IGF2 is frequently seen in BWS 
with similar epigenetic changes observed in sporadic ACC, suggesting a 
common mechanism responsible for IGF2 upregulation [81-84].  Moreover IGF2 
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has been consistently identified as the most upregulated gene in both pediatric 
and sporadic adult ACC [85, 86]. Its cognate receptor Insulin-like Growth Factor 
receptor 1 (IGFR1) is also frequently upregulated whereas the related ligand 
Insulin-like Growth Factor 1 (IGF1) is not [87, 88]. Indeed, IGFR1 is a potential 
therapeutic target as pharmacologic inhibition of the IGFR1 results in inhibition of 
adrenocortical tumor cell growth both in culture and in xenograft model [89].  
Moreover, Zac1, an additional epigenetically regulated gene involved in 
regulation of an IGF2 network of imprinted genes that participate in stem cell 
maintenance is one of the most downregulated genes in pediatric ACC [90, 91]. 
Together these data support a role of the IGF2 signaling pathway in 
adrenocortical carcinoma initiation and/or maintenance. 
The Wnt/β-Catenin pathway has emerged in recent years to be a major 
regulator of both adrenocortical homeostasis and tumorigenesis. Wnt signaling is 
initiated through binding of Wnt ligands to cognate Frizzled (Fzd) receptors which 
results in inactivation of GSK-3β/APC/Axin degradation complex and subsequent 
stabilization of the active signaling molecule, β-Catenin, which translocates to the 
nucleus, bind to TCF/LEF transcription factors to ultimately initiate transcription of 
Wnt-responsive target genes [92]. β-catenin is expressed exclusively in the 
peripheral adrenal cortex of the developing and adult adrenal gland [93]. The 
slow disappearance of the adrenal cortex in adrenal-specific β-catenin null mice, 
together with the restricted subcapsular activation of β-catenin suggests a role of 
Wnt ligands in maintaining adrenocortical homeostasis through regulation of 
peripheral stem/progenitor cells [93]. 
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 Dysregulation of Wnt/β-catenin signaling has also been implicated as an 
initiating event in adrenocortical tumorigenesis. Adenomatis polyposis coli (APC), 
a critical component of the β-catenin destruction complex, is the causative 
mutation in familial adenomatous polyposis coli, a colon cancer syndrome that 
frequently manifests with ACTs [94, 95].  Loss of APC has been shown to result 
in stabilization and constitutive activation of β-catenin and thus could be a 
possible mechanism for the nuclear accumulation of β-catenin seen in ACA and 
ACC [96]. Because APC acts as a tumor suppressor and requires inactivation of 
both alleles, it is not unexpected that APC mutations are rare in sporadic ACC 
[96, 97].  
 Indeed it is not APC but β-catenin that is commonly dysregulated in 
sporadic ACTs, both benign ACAs and malignant ACCs.  15-25% of ACA and 
ACC have been shown to exhibit stabilized nuclear β-catenin [98].  While a 
majority of these ACTs with nuclear β-catenin have been found to harbor 
activating mutations on β-catenin, a subset do not, suggesting perturbation of 
additional upstream mechanisms of Wnt activation (beyond APC and β-catenin 
mutations) are involved in the constitutive stabilization of β-catenin [99-101].  For 
example, in the highly inbred mouse strain DBA2/J, in which gonadectomy has 
been shown to induce subcapsular hyperplasia followed by bona fide 
adrenocortical tumorigenesis, a loss of the Wnt antagonist and putative tumor 
suppressor SFRP1 (Secreted Frizzled-Related Protein 1) was observed in the 
post-gonadectomy ACTs suggesting a dysregulation of Wnt signaling [102].  
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Moreover, in a recent screen of a large cohort of human cancers from a variety 
tissue types the downregulation of SFRP1 was observed[103]. Unfortunately, 
ACTs were not included in this cohort and retrospective review of previous ACC 
cDNA microarray studies does not support SFRP1 as a significantly 
downregulated gene in sporadic ACC with the caveat that SFRP1 expression has 
not been specifically analyzed in the cohort of ACC exhibiting abnormal β-catenin 
nuclear accumulation [86]. 
 The lack of β-catenin mutations in the majority of ACAs (75-85%) 
suggests that there are indeed other mechanisms of ACT initiation and 
progression. Moreover, the presence of β-catenin mutations in both benign ACA 
and malignant ACC suggests that Wnt/β-catenin dysregulation is not sufficient for 
ACC formation. Indeed, the forced constitutive expression of activated β-catenin 
in the mouse adrenal cortex results in adrenal hyperplasia and benign tumors but 
not ACC in aged animals [104]. Together these data support the hypothesis that 
β-catenin serves as an early genetic abnormality that initiates hyperplastic growth 
of adrenocortical cells but is not sufficient to drive development of malignant 
neoplasm but may allow for the accumulation of additional genetic hits such as 
upregulation of IGF2. To test this hypothesis, our group recently published a 
study in which β-catenin was stabilized in adrenocortical cells, through ablation of 
the APC gene, concurrent with an upregulation in IGF2, through a loss of 
imprinting of the IGF2 locus [105]. In mice with stabilized β-catenin, we identified 
adrenal hyperplasia and microscopic and macroscopic adenomas but in 
combination with upregulated IGF2, an increase in macroscopic adenomas and 
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one carcinoma were observed. These data show that β-catenin stabilization is 
sufficient to drive adrenocortical hyperplasia and, in the presence of upregulated 
IGF2, develop adrenocortical tumors. However, the lack of complete penetrance 
of bona fide ACC suggests the involvement of other genes and signaling 
pathways in adrenocortical tumorigenesis. Chapter 2 of this thesis interrogates 
the role of the Notch signaling pathway in ACC. 
 
Basic Biology of the Adrenal Medulla 
 The adrenal medulla is of distinct ontogeny and function from the adrenal 
cortex. While the cortex is mesoderm derived and composed of steroidogenic 
cells, the adrenal medulla is of the neuroectodermal lineage and is composed of 
modified sympathetic neurons called chromaffin cells [106]. The adrenal medulla 
is best characterized as mediating the “fight or flight” response through release of 
the catecholamine hormones epinephrine (adrenaline) and norepinephrine 
(noradrenaline) [107] (Fig 1.6A). The neuroendocrine chromaffin cells of the 
adrenal medulla and extra-adrenal paraganglia, such as the suprarenal ganglia 
and the “organ of Zuckerkandl”, possess the capability to synthesize, store, 
release, and re-uptake catecholamines. Catecholamines are biosynthesized in a 
multi-enzyme process that has been well characterized (See reviews [107, 108]) 
(Fig 1.5). In brief, the rate-limiting enzyme tyrosine hydroxylase (TH), which is 
expressed in every cell of the adrenal medulla and a marker of sympathetic 
neurons in general [109-112], converts the amino acid L-tyrosine into L-dopa, 
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which is in turn converted into dopamine, by aromatic amino acid decarboxylase 
(DOPA decarboxylase, AADC). Dopamine is metabolized to norepinephrine by 
Dopamine β -hydroxylase (DBH), which is then converted to epinephrine by 
phenylethanolamine N-Methyl transferase (PNMT). Of significance, PNMT 
expression is largely restricted to the adrenal medulla and its presence or 
absence defines subpopulations of chromaffin cells that either primarily secretes 
epinephrine (adrenergic) or norepinephrine (noradrenergic) respectively [109, 
110] (Fig 1.6B). The main catecholamine hormone secreted from the adrenal 
medulla is epinephrine (i.e. the medulla is predominantly adrenergic) but the 
relative percentage of chromaffin cells that are adrenergic or noradrenergic 
appears to vary from species to species [113]. Catecholamines are packaged 
into secretory granules that are released into the blood stream through 
exocytosis [107]. Vesicular monoamine transporters (VMATs), a family of 
transporters specific to epinephrine, norepinephrine, and dopamine, are required 
for transport of catecholamines into granules. Two isoform of VMATs exists 
(VMAT1/2) but VMAT1 has been posited as the main isoform expressed in 
chromaffin cells [114].  
CAs are often packaged and co-released with several different peptide 
hormones (Fig 1.6B).  Chromogranins (Chr) are a family of small peptide 
hormones enriched in acidic amino acids that exist in two main isoforms (ChrA 
and ChrB) [110, 115]. Both ChrA and ChrB appear to be expressed exclusively in 
secretory granules, with ChrA immunohistochemically as the most robustly 
expressed in human chromaffin cells (ChrB in mice) and located primarily in 
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adrenergic versus noradrenergic cells [115-117]. ChrA/B have been shown to 
mediate a wide range of cardiovascular effects [115]. Neuropeptide Y (NPY) is 
another peptide hormone concomitantly secreted with epinephrine and 
norepinephrine, and in addition to peripheral effects, may feedback through its 
cognate receptor NPY Y1 on chromaffin cells to modulate catecholamine release 
[118, 119]. 
The thoracic splanchnic nerve, of the sympathetic division of the 
autonomic nervous systems, which releases the neurotransmitter acetylcholine 
(ACh), directly innervates the adrenal medulla and is responsible for the acute 
stimulation of catecholamine release [120, 121] (Fig 1.6A). ACh binds to nicotinic 
ACh receptors (NAchR) expressed on chromaffin cells and induces 
depolarization of chromaffin cells and, in a mechanism similar to neurotransmitter 
stimulation of neurons, culminates if exocytosis of chromaffin granules [107]. In 
addition to ACh, the splanchnic-adrenal synapse releases peptide hormones 
such as pituitary adenylate cyclase-activating peptide (PACAP), which regulates 
a variety of processes in chromaffin cells through its cognate receptor PAC1 [122, 
123]. The significance of PACAP stimulation of chromaffin cells is only recently 
beginning to be appreciated [123].  
Inactivation of catecholamines following secretion occurs through several 
mechanisms. A series of enzymes are able to metabolically convert 
catecholamines into inactive intermediates, which can then be excreted through 
the urine. Monoamine oxidases (MaOs) exists in two isoforms (MaoA/B) which 
are largely active in peripheral sympathetic systems and are involved in 
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inactivation of epinephrine to and norepinephrine to 3,4-dihydroxphenyl 
glycoaldehyde (DHPG) which is subsequently converted to vanillymanedlic acid 
(VMA) and 3-methoxy-4-hydroxyphenylglycol (MHPG), which are excreted in the 
urine [107]. Catechol-O-methyl transferase (COMT) appears to be the 
predominant catecholamine-inactivating enzyme in chromaffin cells and converts 
epinephrine and norepinephrine into the excretable metabolites metanephrine 
(ME) and normetanephrine (NME) respectively [124, 125]. However, the 
metabolism of to ME/NME represents a long-term strategy for inactivation of 
circulating catecholamines. A more immediate response is the sequestration of 
catecholamines back into chromaffin cells through plasma membrane 
transporters of the solute carrier (SLC) family such as the noradrenaline 
transporter 1 (norepinephrine transporter, SLC6A2, NAT1 or NET1) and 
dopamine transporter (SLC6A3, DAT1) (Fig 1.6B). Both NAT1 and DAT1 are 
expressed throughout the adrenal medulla and are selective to both epinephrine 
and norepinephrine [126]. Interestingly, NAT1 expression seems to colocalize 
with PNMT-expressing chromaffin cells, suggesting a specific function in 
adrenergic chromaffin cells [126, 127]. 
 
Development of Chromaffin Cells from the Neural Crest 
 Chromaffin cells are derived from the neural crest (NC), a population of 
transient progenitor cells of neuroectodermal lineage [128, 129] (Fig 1.7). The 
NC cells are pluripotent progenitor cells derived from the junction of the neural 
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tube and the dorsal ectoderm and give rise to numerous cell types in addition to 
chromaffin cells including neurons and glia of the enteric and sympathetic 
division of the autonomic nervous system, melanocytes, skeletal and 
cartaliginous components of the face, C-type thyroid cells, and others (See 
reviews, [106, 130-132]). The NC is specified as early as post-gastrulation [133, 
134]. In a poorly understood process, NC cells delaminate from the dorsal side of 
the neural tube following neurulation. One NC subpopulation, sympathoadrenal 
(SA) progenitors, including progenitors of the sympathetic nervous system, extra-
adrenal paraganglia, and chromaffin cells, migrate towards the dorsal aorta (DO) 
concurrent with expression of the transcription factor aschaete-scute homolog 1 
(Ash1, Mash1 in mice) [135-137] (Fig 1.7A, B). Bone morphogenetic proteins 
(BMPs), specifically BMP-2, 4 and 7, released from the DO have been best 
characterized in specification of SA lineage in the chick embryo, possibly through 
induction and/or maintenance of Mash1 expression [138-141]. Interestingly, 
BMPs have also been implicated in initiation in NC migration [142].  
 In addition to Mash1, a host of other transcription factors has been 
implicated in specification of the SA lineage (Fig 1.7B). The expression of the 
homedomain transcription factor Phox2B has been identified in all peripheral 
sympathetic neurons and appears to be required for their development [143, 144]. 
In a process that appears to be independent of Phox2B expression, Mash1 
induces the expression of Phox2A, which is required for TH and DBH expression, 
markers of sympathetic neurons and chromaffin cells [140, 145-147]. Gata 
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transcription factors, dHand, and others have also been implicated in chromaffin 
cell differentiation post-Mash1/Phox2B/Phox2A induction [148-150]. 
However, the spatiotemporal initiation of Mash1 and Phox2B in SA 
progenitors and how they contribute to chromaffin cell-specific differentiation 
program is still unclear. In some SA progenitors, it appears that Phox2B 
expression may precede Mash1 expression [147, 151]. Mash1 expression is still 
detectable after migration of SA progenitors into the adrenal primordia in contrast 
to loss of Mash1 observed in differentiated sympathetic neurons [140, 152, 153]. 
In Mash1 deficient mice, by E13.5, most cells of the medulla lack TH expression 
but most of the remaining TH-positive cells express Phox2B [152]. Furthermore, 
despite the loss of TH expression, some chromaffin progenitors still express 
Phox2A and dHand, two transcription factors expressed after Mash1 induction, 
while the neuronal marker c-Ret is not downregulated (i.e. the downregulation of 
c-Ret is a common molecular change in chromaffin cell maturation) [152]. These 
data suggests a majority of chromaffin progenitors require Mash1 for suppression 
of the sympathetic phenotype and subsequent differentiation to mature 
chromaffin cells but a distinct subpopulation may only require Phox2B.  In 
contrast, in Phox2B deficient mice, chromaffin progenitors appear to migrate to 
the adrenal primordia by E12.5 but reduce in number and become very sparse by 
E16.5, concurrent with an increase in apoptosis [151]. At E12.5, Mash1 is still 
detectable in Phox2B deficient cells but by E14.5, Mash1, Phox2A, dHand, and 
TH expression are completely absent in virtually every chromaffin cell [151]. 
These data suggest Phox2B may precede Mash1 in chromaffin cell differentiation 
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and is the predominant transcription factor in maintenance of chromaffin cell fate 
[151]. However, these data conflict with the previous study that identified a 
Mash1-dependent chromaffin population. Nevertheless, the specific 
transcriptional program that defines sympathetic neurons versus chromaffin cells 
is still unclear and remains to be elucidated (see reviews [106, 130]) but the 
preceding studies suggest that multiple progenitors may give rise to mature 
chromaffin cells.  
 
The Role of the Adrenal Cortex in Development of the Adrenal Medulla 
 The role of the cortical-chromaffin cell interactions in medullary has been 
the subject of much debate [154]. It was postulated that glucocorticoids secreted 
from the fetal adrenal cortex were required for the maturation of chromaffin cells 
through the induction of PNMT expression, as was shown in isolated rat adrenal 
chromaffin cell progenitors [155, 156]. These data were validated in vivo with the 
generation of mouse line with targeted disruption of Exon2 of the glucocorticoid 
receptor (GR) [157]. The medulla in GR-deficient mice was reduced in size and 
lacked functional PNMT-expressing adrenergic chromaffin cells [157]. However, 
since this mouse was believed to incompletely ablate GR expression, a second 
study reported a mouse line in which Exons 3 was deleted [158]. In these mice, 
the numbers of chromaffin progenitors, as well as expression of molecular 
hallmarks specific to developing chromaffin cells, appear to be unaltered, which 
argues against the role of glucocorticoids in medullary development. However, 
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GR-deficient mice fail to express PNMT that suggests that cortisol is required for 
complete maturation of chromaffin cells [158]. These data were confirmed in a 
conditional knockout mouse of GR in DBH-positive cells, which lacked PNMT-
positive chromaffin cells [159]. Conversely, TH-null mice, supplemented with L-
DOPA during development to bypass the embryonic lethality of these mice, 
exhibited reduced plasma corticosterone levels suggesting reciprocal feedback 
from medulla to cortex [111].  
 Despite these findings, the role of cortical-chromaffin cell interactions in 
medullary development is still ambiguous. In Sf1 knockout or Sf1 heterozygote 
mice, chromaffin cells still migrate to the area where the adrenal gland forms, 
despite the absence of mature Sf1-positive cortical cells [160, 161]. Furthermore, 
these chromaffin still express molecular markers such as TH but, consistent with 
the previous studies, lack PNMT expression. Additionally, downregulation of 
SCG10, a marker of sympathetic neuronal development, was still observed but 
downregulation of c-Ret was not [160, 161]. These studies confirm that 
corticosterone is required for PNMT expression. In a recent study examining the 
status of the adrenal medulla in a variety of mouse models in which cortical 
development is disrupted or ablated, chromaffin cells migrated and differentiated 
normally in many of the mouse crosses analyzed [162]. Taken together, these 
data suggest that development of the adrenal medulla appears to be 
independent of the cortex, with the exception of induction of expression of PNMT. 
Regulation of catecholamine and/or glucocorticoid biosynthesis may involve 
cross talk between the cortex and medulla [109, 154]. 
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Notch Signaling in Tumors of the Adrenal Medulla 
 Pheochromocytomas (PCC) are chromaffin cell neoplasms that secrete 
catecholamines [163, 164].  PCC are rare (2-8 cases/million/year), but generally 
benign tumors, that most commonly manifest in the adrenal medulla (~90% of 
cases) and less frequently in extra-adrenal ganglia (paragangliomas, PGL) [163, 
164]. PCC have classically been shown to clinically manifest with hypertension, 
headaches, palpitations, and diaphoresis as a consequence of hypersecretion of 
catecholamines but, due to a differential catecholamine profile for each tumor, 
symptomatic presentation is actually quite variable [165-168]. The heterogeneity 
in catecholamine production is a consequence of the appropriate expression of 
catecholamine biosynthetic enzymes (i.e. epinephrine-producing PCC express 
PNMT while norepinephrine-producing PCC do not) [169, 170]. Most PCC are 
benign, well encapsulated tumors though about 25% present with metastases, 
but the morbidity and mortality is high in PCC due to symptoms associated with 
catecholamine secretion such as hypertension, stroke and myocardial infarction 
[163, 164].  
 While most PCC are sporadic, about 25-30% of PCC occur in hereditary 
cancer syndromes [171]. Several syndromes have been identified, but only two 
will be discussed here. von Hippel-Lindau (vHL) syndrome is  autosomal 
dominant cancer susceptibility syndrome that presents with an incidence of about 
1 in 36,000 birth/year and is caused by inactivating mutations in the VHL tumor 
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suppressor gene [172-174]. PCC occurs in about 10-20% of vHL patients with 
about 5% of PCC cases diagnosed as malignant [174].  PCC in vHL are 
generally NE secreting and lack PNMT expression [170]. Multiple endocrine 
neoplasia type 2 (MEN2) is another autosomal dominant hereditary cancer 
susceptibility syndrome that presents most frequently with medullary thyroid 
carcinomas but PCC is detected in about 50% of patients (about 5% of these 
PCC are malignant) [164, 175, 176]. MEN2 is caused by activating mutations in 
the proto-oncogene RET, which encodes for the tyrosine kinase receptor c-Ret 
[177]. PCC identified in MEN2 patients frequently over express PNMT and as 
such, is predominantly epinephrine-secreting tumors [170]. The differential 
expression of catecholamines and their respective biosynthetic enzymes may 
suggest different chromaffin cells of origin (noradrenergic versus adrenergic) but 
may also reflect other less defined molecular changes specific to each syndrome.  
Indeed, gene expression profiling of tumors from 12 vHL patients, 7 MEN2 
patients, and 20 sporadic PCC, both epinephrine- and norepinephrine-secreting, 
has revealed common genetic perturbations specific to the predominant 
catecholamine secreted by the neoplasms analyzed [178]. Interestingly, there is 
enrichment of the Notch genes Notch3 and JAG1 in vHL and norepinephrine-
secreting, sporadic tumors compared MEN2 and epinephrine-secreting, sporadic 
tumors and this may have implications for chromaffin cell differentiation (see 
below) [178]. Furthermore, downregulation of 8 genes associated with inhibition 
of Notch1 signaling (the specific genes were not identified) was identified in 13 
malignant versus 45 benign PCC, which suggests inactivation of Notch signaling 
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may be involved in progression to a more aggressive PCC phenotype [179]. A 
similar observation was made in a study examining miRNA expression in 9 
patients with sporadic benign PCC, 8 patients with benign MEN2 PCC, 6 patients 
with benign vHL PCC, and 5 with sporadic PCC that have recurred subsequent 
to surgical resection of the primary tumor [180]. The miRNA Mir-1225-3p was 
found to be upregulated in the sporadic, recurring PCC compared to benign 
tumors. Many of the predicted target mRNAs that Mir-1225-3p may inhibit were 
found to be Notch pathway genes, which imply a downregulation of these genes 
[180]. Taken together, these data indicate a differential activation of Notch 
signaling in PCC. The apparent decrease in Notch gene expression in malignant 
and recurring PCC suggests that Notch may be involved in conferring a more 
quiescent and/or differentiated PCC cell phenotype. Indeed, two studies have 
found that pharmacologic activation of Notch1 signaling through either histone 
deacetylase inhibitors or sodium butyrate inhibits proliferation of the PC-12 rat 
PCC cell line [181, 182].  
In addition to PCC, the adrenal medulla is the origin of about 1/3 of 
pediatric neuroblastoma (NB) tumors [183]. NB presents in 1 in 700 children/year 
and is thus one of the most common childhood cancers, accounting for about 7-
10% of cases/year, and is diagnosed in a majority of patients before 5-years of 
age [184]. The expression of genes normally expressed during development in 
NB suggests an embryonal origin derived from the SA progenitors arrested at 
various stages of differentiation [185-187]. The detection of c-Ret expression 
suggests a sympathetic neuronal precursor-like origin (opposed to a chromaffin 
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progenitor-like origin) of some NB [188]. In contrast to PCC, Notch1 expression 
has been correlated to less differentiated NB and to poor prognosis but 
comparison of expression differences between different types of NB was not 
made in this study [189]. Inhibition of Notch signaling of NB cells lines was also 
found to induce differentiation and retard proliferation of these cell lines [190]. 
However, the cell lines used in this study were not derived from NB of adrenal 
medullary origin. These data suggest Notch functions to maintain the 
undifferentiated state of neural precursors, the over activation of which may lead 
to NB [183]. Even though sympathethtic neuroblasts and chromaffin progenitors 
share a common lineage, contrasting functions of Notch signaling in NB and PCC 
suggest differential role of Notch signaling in the SA lineage. 
Of particular interest in NB pathogenesis is the non-canonical Notch ligand 
Delta-like 1 (Dlk1/FA1/Pref1/ZOG). Dlk1 is a transmembrane protein structurally 
related to other canonical notch ligands; it contains EGF repeats but lacks the 
DSL domain [12, 191]. The role of Dlk1 in Notch signaling is currently unclear. In 
yeast 2-hybrid screens, it has been shown to interact with Notch receptors 
through its EGF repeats [192]. In cell culture, it is hypothesized to antagonize 
Notch receptors in cis (i.e. it inhibits Notch signaling in cell-autonomous manner) 
but this phenomenon has never been shown as consequence of direct interaction 
between Notch receptors and Dlk1 [193, 194]. In development, the function of 
Dlk1 in Notch signaling is far more ambiguous as suggestive by the expression of 
Dlk1 in numerous tissues where canonical Notch signaling is known to occur 
such as the placenta [195, 196], pancreas [197, 198], and lungs [199, 200]. The 
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identification of Dlk1 expression in chromaffin progenitors prior to invasion of the 
fetal adrenal gland, post-invasion, and in the adult gland suggests Dlk1 is a 
molecular marker of differentiated chromaffin cells [199, 201, 202]. Dlk1 
expression has been robustly identified in a subset of NB cells lines concomitant 
with expression of Notch receptors Notch2 and Notch3 and Notch ligand JAG1 
and catecholoamine biosynthetic enzyme DBH [202]. Furthermore, a comparison 
of differentially expressed genes in rat and human PCC identified Dlk1 as one of 
the genes upregulated in PCC from both species [203]. Taken together, these 
data suggest Notch signaling and Dlk1 expression may define a subset of NB as 
derived from SA progenitors committed towards a chromaffin cell fate. These 
data are in contrast to the putative role of Notch signaling in maintenance of a 
less differentiated sympathetic neural precursor in some NB but further research 
is required to define the precise function Notch in tumors of SA lineage.  
 
 
Notch Signaling in the Development of the Neural Crest Lineage 
 The implication of the analysis of Notch in tumors of either adult or 
embryonal SA cells (PCC and NB respectively) is that Notch signaling may be 
involved in the development of this lineage. Notch1, 2 and 3 appear to be 
expressed in non-overlappping patterns in early neurulation and in formation of 
the NC while Notch1 appears to be restricted to NC cells of trunk region, 
precurors to SA progenitors [204]. In the quail embryo, DLL1 expression is 
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restricted to the neural ectoderm prior to NC formation while Notch1 exhibited a 
broad expression pattern throughout the neural fold [205]. Notch1 overactivation 
inhibited NC formation as indicated by loss of the transcription factor Slug, 
believed to be involved in epithelial-to-mesenchymal transition of the neural 
ectoderm in NC initiation, while inhibition of DLL1 had the opposite effect [205]. 
BMP4, a putative signal in initiation of NC formation, was modestly affected in 
these studies [142, 205]. Taken together, these data suggest that Notch signaling 
may participate in initiation of NC formation through transient induction and/or 
maintenance of BMP4 expression. Two similar studies in zebrafish have provided 
additional evidence supporting the function of Notch in specification of the NC 
versus spinal sensory neurons [206, 207]. 
 In addition to its putative role in initiation of development of the NC, Notch 
signaling has been shown to be involved in NC cells later in development. In 
heart development, canonical Notch signaling was inhibited in Pax3-positive cells, 
a marker of cardiac NC cells, which resulted in a wide range of cardiovascular 
abnormalities [208]. Migration of cardiac NC cells was reported as unaffected in 
these mice. However, no effect on SA progenitors and the adult tissues they form 
was reported which is not surprising since cardiac NC cells are considered 
distinct from the NC cells that give rise to SA progenitors [132, 208].  
In sympathetic ganglia of the developing chick embryo, DLL1, Notch1, and 
Hes5 expression was detected in early in development of sympathetic ganglia 
but this expression was severely reduced at later embryonic time points [209]. 
When Notch signaling was constitutively activated in developing sympathetic 
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ganglia, a reduction in the number of SCG10-positive neurons was observed 
while the opposite was observed with the introduction of a dominant-negative 
inhibitor of Notch transcription [209]. These data suggest Notch may suppress 
differentiation of sympathetic neurons from SA progenitors. No evidence on 
whether Notch may drive SA progenitors towards a chromaffin cell fate was 
provided in this study but the common lineage between the two cell populations, 
including expression of several SA-specific transcription factors, presupposes 
this possibility. As previously discussed, the nan-canonical Notch ligand Dlk1 is 
expressed in chromaffin progenitor pre- and post-migration into the adrenal 
anlage [199, 201, 202]. However, no further characterization of Notch signaling in 
chromaffin cell progenitors or adult chromaffin cells have been performed. 
Chapter 3 of this thesis addresses the role of Notch signaling in the development 










Figure 1.1: The Notch Signaling Pathway. A. Basic structure of Notch 
receptors. NECD: Notch extracellular domain, NTMICD: Notch 
transmembrane/intracellular domain, NICD: cleaved Notch intracellular domain, 
NRR: negative regulatory region, LNR: cysteine-rich LIN12-Notch repeats, HD: 
heterodimerization domain, TM: transmembrane domain, RAM: RBPjκ 
association module, ANK: ankyrin repeats, TAD: transactivation domain, NLS: 
nuclear localization signals, PEST: proline/glutamic acid/serine/threonine-rich 
domain S2, S3/4 cleavage sites are indicated with arrows B. DSL: 
delta/serrate/lag-2 domain, DOS: Delta and OSM-11-like protein domain, CR: 
cysteine-rich region, TM: transmembrane domain. C. Overview of the basic 
Notch signaling. Ligands and receptors expressed on adjacent cells interact 
through their extracellular domain. Upon Ligand/receptor transendocytosis, the 
S2 site is exposed and cleaved by ADAM metalloproteases. The γ -secretase 
complex then cleaves at S3/4 site, which results in release of the NICD. The 
NICD transits to the nucleus where it interacts with DNA-bound CSL protein and 















































Figure 1.2: Biology of the Adrenal Gland. A. Endocrinology of the 
Hypothalamic-pituitary-adrenal axis. In response to stress, corticotropin releasing 
factor (CRF) released from the hypothalamus acts on coricotropes of the anterior 
pituitary gland to stimulate release of adrenocorticotropic hormone (ACTH). 
ACTH stimulates secretion of cortisol from the adrenal cortex, which flows 
through the blood stream to induce systemic metabolic effects in addition to 
regulating the secretion of CRF and ACTH though a negative-feedback loop. B. 
The discrete zones of the adrenal gland and their respective hormone secretions. 
The adrenal cortex is marked by expression of the nuclear receptor steroidogenic 
factor 1 (Sf1), is enclosed by a mesenchymal capsule, and is composed of three 
concentric zones. The outer Zona Glomerulosa secretes mineralocorticoid 
hormones such as aldosterone. The middle Zona Fasiculata produces the 
glucocorticoid hormone cortisol (corticosterone in mice). The inner Zona 
reticularis (not present in mice) secretes sex steroid precursors such as 
dihydroepiandosterone (DHEA) and DHEA-sulfate (DHEA-S). The inner medulla, 
marked by tyrosine hydroxylase (TH) expression and of distinct ontogeny from 
the adrenal cortex, secretes catecholamine hormones epinephrine (E) and, to a 

















































Figure 1.3: Development of the Adrenal Gland. Formation of the bipotential 
adrenogonadal primordium (AGP) is initiated by expression of steroidogenic 
factor 1 (Sf1) expression around E10.5 in mice. The AGP bifurcates into the 
adrenal and gonadal primordial at approximately E11.5. Invasion of the fetal 
adrenal gland (adrenal primordia) by chromaffin progenitor cells begins at E12 
and ceases around E14. This is concurrent with encapsulation of the adrenal 
cortex by mesenchymal cells. The definitive (adult) cortex begins to develop 
shortly after birth concomitant with the regression of the fetal adrenal and is 
complete by about P21. A residual fetal (X-zone) persists until puberty in males 































Figure 1.4: Adrenocortical Tumorigenesis. Adrenocortical adenomas (ACA) 
are benign tumors that are common, benign, well differentiated, and generally 
encapsulated. Overactivation of the Wnt signaling pathway through of variety of 
mechanisms has been implicated in ACA formation. Adrenocorticacarcinomas 
(ACC) are rare tumors but are highly aggressive and frequently fatal. ACC are 
composed of heterogenous population of cell types, and are highly invasive and 
vascularized, and frequently have metastasized upon detection. Overactivation of 
the Insulin-like growth factor (IGF) pathway, especially upregulation of IGF2, 
concurrent with overactivation of the Wnt pathway has been posited as critical 
genetic hits in ACC formation. The status of the Notch pathway is unknown in 










































Figure 1.5: Biosynthesis of Catecholamines. Catecholamine hormones are 
derivatives of the amino acid L-tyrosine, which is enzymatically converted to L-
DOPA by the critical, rate-limiting enzyme tyrosine hydroxylase, expressed in all 
chromaffin cells of the adrenal medulla. L-DOPA is converted to Dopamine by 
aromatic L-amino acid decarboxylase (DOPA decarboxylase), which is 
subsequently converted to norepinephrine by dopamine-β-hydroxylase. In the 
adrenal medulla, norepinephrine is converted to epinephrine by 
phenylethanolamine-N-methyltransferase but only in chromaffin cells that 


























(Adapted from www.wikipedia.com) 
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Figure 1.6: Basic Molecular Biology of Chromaffin Cells of the Adrenal 
Medulla. A. Direct innervation of the adrenal medulla is through the thoracic 
splanchnic nerve, which releases the acetylcholine (ACh) and pituitary adenylate 
cyclase-activating protein (PACAP) and induces secretion of the catecholamine 
hormones epinephrine and norepinephrine during the “fight or flight” stress 
response. B. Important molecules in adrenergic chromaffin cell biology. 
Adrenergic chromaffin cells express the enzyme PNMT that is required for the 
conversion of norepinephrine to epinephrine (E). Catecholamines are transported 
into chromaffin granules through vesicular monoamine transporters (VMAT1 is 
the predominant VMAT in chromaffin cells). Peptide hormones chromogranin A 
(ChrA) and neuropeptide Y (NPY) are concurrently packaged into chromaffin 
granules. Granule exocytosis and release of the enclosed hormones is mediated 
through splanchninc nerve mediated release of ACh and PACAP, which bind to 
nicotinic acetylcholine receptors (NAChR) and PAC1, respectively. Cessation of 
the “fight or flight” induced catecholamine release is partly mediated through 
reuptake of catecholamines back into chromaffin cells through the solute carrier 
family of plasma membrane transporters that include dopamine transporter 1 
(DAT1) and noradrenaline transporter 1 (NAT1). NPY released with 


















































































Figure 1.7: Development of Chromaffin Cells. A. Migration of SA progenitors 
into the adrenal anlage. Multipotent neural crest  (NC) progenitors arise from the 
dorsolateral sides of the neural tube (NT) post neurulation. Shortly after, NC cells 
of the sympathoadrenal (SA) lineage begin to migrate between the somites (SO) 
and receive inductive signals in transit and from the dorsal aorta (DO), 
committing them towards a SA progenitor fate. Migration and initial differentiation 
of SA progenitors is complete by about E10.5 in mice. After separation of the 
adrenal primordia (AP) and gonadal primordial (GP) (about E11.5 in mice), SA 
progenitors that are destined to become chromaffin cells begin to migrate into the 
AP (E12.5 in mice), which is complete by E14.5. Independent of chromaffin 
progenitors into the AP, other SA progenitors migrate and form sympathetic 
ganglia (not shown). B. Maturation of cells of the SA lineage. Commitment of 
multipotent NC progenitors towards the SA lineage is initiated through bone 
morphogenic protein (BMP) signals; BMPs may also initiate migration of SA 
progenitors to the DO. The SA lineage is defined by expression of the 
transcription factors Mash1 and Phox2B, which induces the expression of the 
downstream transcription factors Phox2A, Gata3, and dHand. Ultimately, SA 
progenitors express TH and dopamine-β-hydroxylase (DBH), enzymes common 
to both cells of the sympathetic nervous system, adrenal medulla, and extra-
adrenal paraganglia. In a poorly understood process, SA progenitors are 
committed towards either a sympathetic neuronal or chromaffin cell fate. 
Downregulation of neuronal markers SCG10 and c-RET, as well as induction of 
chromogranin A and B (ChrA/B) and the epinephrine-synthesizing enzyme PNMT, 
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are molecular hallmarks of mature, adrenergic chromaffin cells (Noradrenergic 
























































































































































































































































































































































































































































































































































































































































































Chapter 2: The Role of Notch Signaling in Adrenal 
Cancer* 
Abstract 
Adrenocortical adenomas (ACA) are common (~4% of the population) benign 
neoplasms of the adrenal gland while adrenocortical carcinomas (ACC) are rare 
(~0.5-2 cases/million) highly malignant cancers. Due to difficulty of detection and 
lack of effective treatments, ACC frequently presents with an extremely poor 
prognosis. Despite recent technological advancements in genetic profiling of 
ACC, the molecular pathogenesis of ACC has remained unclear, particularly 
pertaining to factors involved in late-stage disease.  Interrogation of our recent 
adrenocortical tumor cDNA expression array data set identified an upregulation 
of the Notch ligand JAG1 in ACC compared to ACA and normal adrenals. Notch 
signaling is a highly conserved developmental signaling pathway that involves 
interaction between a transmembrane ligand (JAG1) and its cognate receptor 
(Notch) expressed on adjacent cells. To interrogate the role of JAG1 in ACC, the 
Y1 mouse ACC cell line was identified as an ACC cell line that exhibits JAG1 
activated Notch signaling. Experiments employing a Jag1 knockdown strategy 
                                                        
* Portions of this chapter are published in the following publication: 
Simon DP, Giordano TJ, Hammer GD. Upregulation of JAG1 Enhances ACC Cell 
Proliferation in Adrenocortical Carcinoma. Clin Cancer Res. 2012. 18:2452-2464. 
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and utilizing a co-culture system with FACS analysis reveal a non-cell 
autonomous inhibition of proliferation in the Y1 cell line. Furthermore, inhibition of 
Notch-dependent transcription phenocopies the Jag1 knockdown. Lastly, JAG1 is 
positively correlated with both advanced stage and mitotic rate in patients with 
ACC in addition to markers of proliferation KI67 and TOP2A. Taken together, the 
data indicate that JAG1 augments cell proliferation in a non-cell-autonomous 
manner, consistent with a role of the Notch pathway activation in ACC initiation, 
maintenance or progression. JAG1 and the Notch signaling pathway may be 
novel targets for therapeutic intervention in late-stage ACC. 
 
Introduction 
 Adrenocortical Tumors (ACT) are extremely common neoplasms, the vast 
majority being benign adrenocortical adenomas (ACA) that occur in as many as 
4-7% of the population whereas adrenocortical carcinomas (ACC) are extremely 
rare (~0.5-2 cases/million) accounting for 0.2% of cancer deaths annually [1, 2]. 
ACC is typically an aggressive neoplasm with many patients presenting with 
metastases upon diagnosis [1]. Due to difficulty of early detection and lack of 
effective treatments for advanced-stage ACC, the average survival for surgically 
unresectable tumors is 12-months and the overall 5 year survival is historically 
less than 10% [3, 4]. The molecular pathogenesis of ACC has remained elusive 
until recently. Dysregulation of developmental signal transduction pathways is 
found in an increasing number of cancers including ACC. Specifically, the Wnt 
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signaling pathway, a critical mediator of adrenal development, plays an important 
role in the etiology of ACC, where constitutively active, nuclear β -catenin is 
frequently observed [5-9]. The development of visible adrenal tumors in mice 
engineered to express constitutively-active β-catenin in the mouse adrenal cortex 
supports the hypothesis that dysregulation of Wnt/β-catenin signaling is a vital 
step in adrenocortical tumorigenesis [10]. 
 Similar to the Wnt pathway, Notch signaling is involved in a wide range of 
cell fate decisions during development. While its dysregulation is a common 
molecular event in a variety of cancers, its role in adrenal development and ACC 
is unknown [11, 12]. Notch signaling involves interaction between a 
transmembrane ligand, of either the Jagged (JAG1/2) or Delta-like (DLL1/3/4) 
family, and a transmembrane receptor (NOTCH1/2/3/4) generally expressed on 
adjacent cells [13, 14]. Upon binding of Notch ligand to receptor, the γ-secretase 
complex cleaves the Notch receptor in two locations releasing the active 
signaling molecule NICD (cleaved Notch intracellular domain). NICD interacts 
with constitutively DNA-bound CSL (CBF-1/RBPjκ/Su(H)/Lag-1), recruits the 
essential transcriptional coactivator MAML (Mastermind-like) and initiates 
transcription of Notch-dependent genes such as the HES (hairy enhancer of split) 
family of transcription factors. 
 The upregulation of the Notch ligand, Jagged1 (JAG1), in a variety of 
cancers implies a ligand-dependent activation of the Notch signaling pathway 
[15-19]. Indeed, the upregulation of JAG1 in breast and prostate cancer has been 
implicated in metastatic disease and correlates with poor prognosis [20-23]. 
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Mechanistically, JAG1 is thought to enhance the metastatic potential of breast 
cancer through a Notch-dependent induction of epithelial-to-mesenchymal 
transition of mammary epithelial cells [24]. Like all Notch ligands, JAG1 
classically interacts with receptors on adjacent cells (non-cell-autonomous) rather 
than with receptors on the cells in which they are expressed (cell-autonomous). 
However, the ability of JAG1 to induce malignant transformation of RKE cells 
despite the absence of Notch receptors raises the possibility that non-canonical 
actions of JAG1 mediate some of its oncogenic manifestations [25]. In this study, 
we report for the first time that JAG1 is the primary upregulated Notch ligand in 
ACC and enhances ACC cell proliferation and tumor aggressiveness in a non-
cell-autonomous manner through activation of Notch signaling in adjacent cells. 
 
Materials and Methods 
Microarray Analysis 
 DNA Microarray analyses were performed with Affymetrix U133A 2.0 Plus 
oligonucleotide arrays and have been published [26, 27]. Probe sets for JAG1, 
JAG2, DLL1, DLL3, and DLL4 were presented in a heatmap with clustering 
delineated by tumor type; individual samples were ordered based on JAG1 
expression as determined by probe sets 216268_s_at and 209099_x_at. For a 
complete list of probe sets of Notch pathway genes used in dot plots and 
correlations (Fig 2.1-2.3), see Table 2.1. Additional correlations were performed 
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using JAG1 probe set 216268_s_at with KI67 212022_s_at, and with TOP2A 
201292_at. Similar correlations were obtained with other JAG1 probe sets. 
 
Human Samples 
 Protein and RNA were extracted using routine protocols from frozen 
adrenocortical tissues obtained via the University of Michigan Comprehensive 
Cancer Center Tissue Procurement Service with IRB approval. Samples for 
protein and RNA analysis were randomly selected [normal adrenal (NL): n=5, 
ACA: n=5, ACC: n=10]. Due to tissue availability, different pools of samples were 
analyzed for message and protein. 
 
Plasmids, shRNA and transfection  
Notch reporter (pJH23A: 4xwtCBF1Luc) and Control Reporter (pJH25A: 
4xmtCBF1Luc) expression vectors were a generous gift from Dr. S. Dianne 
Hayward (John Hopkins University Medical School, Baltimore, MD) [28]. The 
Notch reporter contains four consensus CSL binding sites driving expression of 
firefly luciferase while these sites are mutated in the Control Reporter. pGIPZ 
vectors (Open Biosystems, Huntsville, AL)  expressing shRNA against JAG1 and 
a non-specific scrambled control shRNA (Scramble) were obtained from the 
University of Michigan shRNA core (http://fgc.lsi.umich.edu/index.html). In 
addition to the shRNA, pGIPZ vectors contain a puromycin selection cassette 
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and an IRES GFP sequence. Sequences for JAG1 shRNA are #1: 5’-
gtcagaattgtgacataaa-3’ and #2: 5-gggatttggttaatggtta-3’. pdsREDII expresses 
dsREDII under control of the CMV promoter and was obtained from Dr. Claudius 
Vincenz (University of Michigan, Ann Arbor, MI). Control (MigR1) plasmid, which 
expresses GFP, and DNMaml plasmid, which expresses a fusion protein of GFP 
and amino acids 13-74 of Maml1 and acts as a dominant-negative, were a 
generous gift of Dr. Ivan Maillard (University of Michigan) [29, 30]. Both Control 
(MigR1) and DNMaml plasmids contain flanking LTR sequences and expression 
is driven by an MSCV promoter. Retroviral packaging protein expression 
plasmids pGag/Pol and pVSV were kindly provided by Dr. Michael Malim (King’s 
College, London, UK).  
  
Cell Culture and Generation of Stable Cell Lines 
Culture of the mouse ACC cell line Y1 [31] and the Human ACC cell lines 
NCI-H295A [32] and RL251 [33] has been described previously [27, 34]. All 
standard cell culture reagents were obtained from Invitrogen Life Technologies 
(Carlsbad, CA). MOLT4 T-ALL cell line (Item # CRL-1582) was obtained through 
American Type Culture Collection (ATCC, Manassas, VA).  Virus-competent 
293T cells, a gift from Dr. Benjamin Margolis (University of Michigan), were 
maintained in DMEM with 10% Cosmic Calf Serum (CCS, Hyclone, Logan, UT) 
and penicillin/streptomycin. In some experiments, Y1 cells were treated for 6h 
with 5mM EDTA prepared in PBS. Transient transfections were performed using 
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Fugene (Roche, Madison, WI) according to the manufacturer’s instructions and 
optimized at a 4:1 ratio (4µl Fugene/1µg DNA) for Y1 cells and 2:1 ratio for 293T 
cells. 
For generation of Scramble (GFP+) and Jag1KD (GFP+) stable cell lines, 
Y1 cells were transfected with 2µg of pGIPZ vectors expressing shRNA directed 
against Jag1 or a control (Scramble) as described above, followed by 4 weeks of 
puromycin selection (2µg/ml, Roche). Cells were then enriched for GFP 
expression within the 104-105 range using Fluorescence Activated Cell Sorting 
(FACS) as described below. Sorted cells were replated in 10cm dishes and 
allowed to expand.  
To obtain the dsREDII [wildtype Y1 (Red+)] cell line, 10cm dishes of Y1 
cells were transiently transfected with 2µg of pdsREDII as described. Because 
pdsREDII lacks a mammalian selection cassette, cells were passaged after 2 
days and were transiently transfected an additional time. After 2 days enriched 
for with high dsREDII expression within the 104-105 range by FACS. Sorted cells 
were replated in 10cm dishes and allowed to expand. 
To generate the Control (GFP+) and DNMaml (GFP+) stable cell lines, 
viral supernatant was generated by contransfection of 293T cells with 2µg each 
of pGag/Pol, pVSV, and either Control (MigR1) or DNMaml constructs. After 2 
days, medium was collected and centrifuged at 5,000xg followed by filtration 
through a 0.22µM syringe nylon filter (Fisher Scientific, Pittsburgh, PA). Viral 
supernatant was adjusted to a final volume of 10ml with DMEM and polybrene 
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was added (10U/ml, Sigma, St. Louis, MO). Y1 cells were then transducted with 
viral supernatant for 24 hours. Cells were passaged and transducted an 
additional time under identical conditions. Cells were then enriched for GFP 
expression within 104-105 range using FACS and were replated into 10cm dishes 
and allowed to expand. Because the GFP and dsREDII expression diminished 
overtime, cells were resorted under identical parameters every 3 months. 
 
Fluorescence Activated Cell Sorting and Analysis 
 Trypsinized cells were pelleted at 1,000xg for 5min and resuspended in 
1X PBS containing 10% CCS at a concentration of 1-2million cells/ml. FACS 
experiments were performed by the University of Michigan Flow Cytometry Core 
(http://www.med.umich.edu/flowcytometry/) with either BD Biosciences 
FACSDiVa High-Speed Cell Sorter (3-laser: 488nm, 350nm and 633nm) or BD 
Biosciences FACSAria High-Speed Cell Sorter (3-laser: 488nm, 407nm and 
633nm).  
 
Quantiative real time-PCR (QPCR) Analysis 
 RNA was isolated with TRIzol (Invitrogen, Carlsbad, CA) according the 
manufacturer’s instructions and cDNA was generated using iScript cDNA 
Synthesis kit (Bio-Rad Laboratories, Hercules, CA). QPCR experiments were 
performed as previously described [35, 36]. A comprehensive list of human and 
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mouse QPCR primers is found in Table 2.2. Analysis was conducted with either 
the efficiency-corrected ΔCT method or the ΔΔCT method as indicated [37]. 
Expression of mRNA was normalized to β-actin. 
 
Immunocytochemistry and Immunoblots 
 For a comprehensive list of primary and secondary antibodies used for 
Immunocytochemistry (ICC) and Immunoblots see Table 2.3. For 
immunocytochemical localization:  Y1 cells were plated on glass slides coated 
with fibronectin (10µg/ml, Sigma). Slides were washed in 1X PBS, fixed in 4% 
paraformaldehyde (Fisher) for 15min at 4°C, and permeabilized with 0.02% 
Igepal CA-630 (Sigma). Slides were blocked with 2% milk in 1X PBS and 
primary/secondary antibodies (Table 3.3) were diluted in 0.2% milk in 1X PBS.  
For detection of native fluorescence, slides were not fixed in order to preserve 
the activity of GFP and dsRedII. Cover slips were applied and images obtained 
as previously described [35, 36].  
 Immunoblot analysis of protein lysates from cell cultures were performed 
as previously described[35]. Analysis of some protein lysate was conducted as 
described but blocking, primary, and secondary dilutions were done in Odyssey 
Blocking buffer (LICOR, Lincoln, NE), secondary antibodies used were Odyssey 
IRdyes (Table 3.3). Immunoblots using protein lysate from human adrenal tumor 
samples was quantified using ImageJ software (National Institutes of Health, 
Bethesda, Md). The btan20 (Notch1) and C651.6DbHN (Notch2) monoclonal 
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antibodies were developed by Spyros Artavanis-Tsakonas and were obtained 
from the Developmental Studies Hybridoma Bank under the auspices of the 
NICHD and maintained by the University of Iowa, Department of Biological 
Sciences, Iowa City, IA, 52242. 
 
MTS Proliferation Assay 
 The MTS cell viability assay translates cell number into a colorimetric 
readout (absorbance) via metabolic breakdown of tetrazolium salts (Promega 
Corp, Madison, WI). Cells were plated in 96-well plates and assay performed 
according to the manufacturer’s instructions. Absorbance values were obtained 
using a SpectraMAX190 plate reader (Molecular Devices, Sunnyvale, CA). 
 
Co-culture Experiments 
 Stable cell lines of Y1 cells expressing dsRedII [ wildtype Y1 (Red+)] were 
co-cultured with either Scramble (GFP+) or Jag1KD (GFP+) Y1 cells in triplicate 
wells of a 6-well plate in two ratios: 90% Red+/ 10% GFP+ and 10% Red+/ 90% 
GFP+. The combined initial concentration for each ratio at each time point was 
150,000 cells/well. Cells analyzed at the Day 4 time point were plated 4 days in 
advance of analysis, Day 3 time point were plated 3 days in advance of analysis, 
etc.  At the end of the 4-day time course, harvested cells were analyzed by FACS 
as described above.  10,000 cells were analyzed for each sample and the cell 
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number for each color (Red+ or GFP+) was determined and data are presented 
as a percentage change from Day 1 (For schematic, Fig 4A). Identical conditions 
and analysis were performed for co-culture of wildtype Y1 (Red+) with either 
Control (GFP+) or DNMaml (GFP+) except that a 50%/ 50% ratio was used. 
 
Luciferase Assays  
 Y1 cells were plated in 24-well plates and were transiently transfected with 
50ng of pRL-TK Renilla Luciferase (Promega Corp, Madison, WI) and 0.5µg of 
either Control Reporter (pJH25A) or Notch Reporter (pJH23A) firefly luciferase 
constructs described above. Assays were performed 24h after transfection using 
the Dual-Luciferase Reporter Assay (Promega) according to the manufacturers 
instructions and optimized for Y1 cells. Cells were lysed in 1X Passive Lysis 
Buffer and lysates analyzed on the Glomax Multi-detection System (Promega). 
Expression was normalized to pRL-TK Renilla Luciferase.  
 
Pharmacologic Inhibition of Notch Signaling 
 Y1 and MOLT4 cells were plated in 6-well plates and were treated with 
either vehicle (DMSO) or 100µM of DAPT (D5942, Sigma) for 24h. Cells were 
harvested for protein and mRNA analysis. Y1 cells were plated in 6-well plates 
and were treated with vehicle (DMSO) or 100, 250, 400, 500ng of Compound E 
(γ-secretase inhibitor-XXI, Cat #: 565790, CEMD Biosciences Inc., San Diego, 
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CA). Cells were harvested after 24h for protein and mRNA analysis. Inhibitory 
Notch antibodies were acquired from Genentech (San Francisco, CA) and have 
been described previously [38]. Y1 cells were plated in 24-well plates and treated 
with Vehicle (PBS) or 80ng of either anti-Notch1 (YW169.60.79, PUR20635), 
anti-Notch2 (YW163.54.76, PUR23852) or a combination of both for 4h or 24h. 
Cells were harvested for mRNA analysis. 
 
Statistics 
 All comparisons made used the student’s T-Test. Statistical analysis of 
microarrays has been described elsewhere [26, 39]. 
 
Results 
JAG1 is Upregulated in Human ACC. 
 In an effort to better understand the molecular characteristics of human 
ACC, our group has previously performed DNA microarray analyses using frozen 
human tissues – most recently with a total of 33 ACC, 22 ACA, and 10 normal 
adrenals (NL) [26, 39]. Analysis of differentially-expressed probe sets revealed 
an upregulation of the Notch ligand JAG1 in ACC samples compared to normal 
and adenomatous tissue (Fig 2.1A). The five JAG1 probes sets depicted are 
within the top 0.8% of all rank-ordered upregulated probe sets represented in the 
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microarray. The other four Notch ligands (JAG2, DLL1/3/4) were upregulated in 
only a few ACC.   
Quantitative analysis of two independent probe sets for each JAG ligand 
(JAG1 and JAG2) confirmed that JAG1 expression is significantly higher in ACC 
samples compared to NL and ACA (Top panels, Fig 2.1B). JAG2 exhibits a 
statistically significant, albeit less dramatic, difference in expression among 
samples (Bottom panels, Fig 2.1B). Furthermore, interrogating two other adrenal 
tumor microarray data sets revealed a similar upregulation of JAG1 in ACC[39, 
40].  
 Microarray analyses were validated with QPCR of mRNA from human 
adrenal tumor samples (Fig 2.1C).  Correlation of QPCR and microarray data for 
each samples is shown in Fig 2.1D. While both JAG1 and JAG2 were 
significantly different in ACC vs ACA/NL, JAG1 is expressed at a higher level and 
a greater increase in ACC than JAG2. Additionally, JAG1 QPCR expression was 
more tightly correlated to the microarray data (JAG1: r=0.874, JAG2=0.545). 
These data support the validity and biological relevance of the microarray results. 
 Furthermore, immunoblot analysis of human adrenal tumor samples 
revealed a higher expression of JAG1 protein in the majority of ACC when 
compared to NL and ACA (Top panel, Fig 2.1E). Quantification of band intensity 
of two immunoblots using the same set of human samples identifies robust 
protein levels of JAG1 in most ACC and barely detectable quantities in ACA and 
NL (Bottom panel, Fig 2.1E). Together these data suggest that JAG1 mRNA and 
  70 
protein is upregulated in a majority of ACC samples and is consistent with 
biological relevance of JAG1-activated Notch signaling contributing to 
adrenocortical carcinogenesis. While JAG2 is also upregulated, it exhibits a lower 
level of expression and a poorer correlation of QPCR and array data.  Therefore, 
we decided to focus exclusively on JAG1, the significance of its upregulation in 
ACC, and its role in adrenocortical carcinogenesis. 
 
Notch Receptors and Target Genes Exhibit Variable Expression in ACC. 
 Since JAG1 is hypothesized to mediate its functions through interaction 
with Notch receptors, the expression of Notch receptors (Notch1-4) was analyzed 
in our microarray data set (Fig 2.2). Quantitative analysis of dot plots of two 
independent probe sets for Notch1-3 and one probe set for Notch4 revealed no 
significant change in expression ACC compared to ACA and NL for a majority of 
the probe sets analyzed. However, Notch2 Probe Set #1 did exhibit a modest 
albeit significant upregulation in ACC compared to NL and in ACA vs NL (Fig 
2.2A) but no positive correlation to JAG1 expression was identified (Fig 2.2B, top 
panel). Microarray analysis of Notch2 expression was validated with QPCR of 
mRNA from human adrenal tumor samples in which many ACC samples 
exhibited higher mRNA expression of Notch2 compared to benign ACA and NL 
adrenals (Fig 2.2C). Interestingly, some ACA samples did show increased 
Notch2 expression. Similarly, Notch3 Probe Set #2 exhibited a statistically 
significant increase in expression in ACC compared to ACA and NL. We also 
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identified a modest, statistically significant, positive correlation between NOTCH3 
and JAG1 expression (r=0.29, p=0.02, Fig 2.2B, bottom panel). These data 
reveal that Notch2 and Notch3 are upregulated in ACC while Notch1 and Notch4 
are not. However, the lack of strong correlations with JAG1 expression suggests 
that a concurrent upregulation of Notch receptors may not be required to facilitate 
augmented Notch ligand-receptor signaling in ACC. 
 Next, we considered the expression of Notch target genes that have been 
confirmed targets in numerous systems, Hes1 and Hey1 (Fig 2.3) [11, 13]. 
Quantitative analysis of dot plots of two independent probe sets for Hes1 and 
Hey1 revealed a significant change in expression of Hey1 in ACC compared to 
ACA and NL for both probe sets but no significant changes for either Hes1 probe 
set (Fig 2.3A). Both Hey1 probe sets also exhibited positive correlations with 
JAG1 expression (Probe Set #1: r=0.34, p=0.0053, Probe Set #2: r=0.34, 
p=0.0054) (Fig 2.3B). QPCR of mRNA from human adrenal tumor samples 
validated the upregulation of Hey1 in ACC (Fig 2.3C, bottom panel). In contrast 
with the microarray data, elevated mRNA of Hes1 was also detected in both ACA 
and ACC samples (Fig 2.3C, top panel). These data reveal that Notch target 
genes are significantly upregulated in ACC although numerous other targets not 
considered in our analysis may be regulated by Notch signaling in adrenocortical 
tumorigenesis. 
 
The Y1 Mouse ACC Cell Line Exhibits Active Notch Signaling 
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 Predicated on the canonical role of JAG1 as an obligate ligand for Notch 
activation, normal mouse adrenal (Adrenal), the mouse ACC cell line (Y1), and 
the two cell lines derived from human ACC (H295A and RL251) were surveyed 
for concurrent Jag1 abundance and expression of the Notch signaling 
components. Jag1 protein is highly expressed in both Y1 and H295A lines, 
recapitulating in an in vitro context the upregulation of JAG1 observed in the 
human ACC samples (Fig 2.4A), with Jag1 mRNA showing a 43-fold increase 
over Jag2 and Dll1/3/4 ligands being barely detectable (Fig 2.4B). This latter 
comparison demonstrates that the Y1 cell recapitulates the Notch ligand 
expression profile observed in the human ACC microarray where the expression 
of the other four Notch ligands is only modestly elevated and is consistent with 
Jag1 functioning as the biologically relevant Notch ligand in Y1 cells. Y1 cells 
also express both the Notch1 and Notch2 receptors together with the active 
signaling molecule NICD. Immunocytochemistry (ICC) reveals ubiquitous 
expression of core Notch pathway components (ligand: Jagged1, receptors: 
Notch1/2, target gene: Hes1) in Y1 cells (Fig 2.4C), suggesting that juxtaposed 
Y1 cells are capable of activating canonical Notch signaling in adjacent cells 
and/or are capable of self-activation (ie: ligand-mediated receptor activation). 
 The active engagement of Notch signaling in Y1 cells provides an 
appropriate model system to examine Jag1-dependent Notch activation in ACC. 
Because Mg2+ is required for Notch receptor stability, Mg2+ depletion can be 
used to induce Notch receptor cleavage and biochemically release the active 
NICD peptide in order to test induction of Notch-dependent transcription (as 
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opposed to ligand-independent constitutively active Notch-mediated 
transcription) in Jag1-expressing tumor cells [41, 42]. Treatment of Y1 cells for 6 
hours with the chelator EDTA to deplete Mg2+ resulted in an increase in NICD 
protein in EDTA treated cells versus vehicle treated cells (Top panel, Fig 2.4E). 
H295A human ACC cells also exhibited a similar response to EDTA treatment 
(Fig 2.4F). To confirm NICD cleavage results in productive Notch-dependent 
transduction, Y1 cells were transiently transfected with a specific Notch luciferase 
reporter containing four NICD-consensus binding sites or an otherwise identical 
reporter in which the NICD sites are mutated (Fig 2.4D). Following EDTA 
treatment, an increase in the expression of the Notch luciferase reporter was 
observed (EDTA-Notch versus Vehicle-Notch = 2.3 fold increase, bottom panel, 
Fig 2.4E). These data indicate canonical Notch signaling can be activated in Y1 
cells, presumably due to the presence of Jag1.  
 Because Notch signaling is generally dependent upon the juxtaposition of 
two adjacent cells expressing membrane-bound ligand and receptor respectively, 
we hypothesized that activation of Notch signaling in Y1 cells is density 
dependent. When Y1 cells were plated at increasing density (10%, 25%, 50%, 
90% confluence) a density-dependent increase in NICD protein was observed 
(Top panel, Fig 2.4G). When the transcriptional activity of the Notch reporter was 
evaluated by luciferase assay, an elevated activity was observed in the highest 
(90%) when compared to the lowest (10%) density (High Density-Notch versus 
Low Density-Notch = 2.3 fold, bottom panel, Fig 2.4G).  Additionally, immunoblot 
analysis did not detect Jag1 in conditioned medium from Y1 cells, which 
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eliminates the possibility that Jag1 is acting as a secreted factor (data not shown). 
Taken together, these data confirm active Notch signaling is occurring in Y1 cells. 
 To investigate the dependence of Notch activation on Jag1 in ACC cells, a 
shRNA knockdown strategy was employed. Two shRNAs with 100% homology to 
Jag1 mRNA were found to be sufficient to knockdown Jag1 in Y1 cells when 
used in combination. Two stable cell lines were generated, a Jag1-knockdown 
line expressing both Jag1 shRNAs [Jag1KD (GFP+)] and a control line 
expressing a non-specific shRNA [Scramble (GFP+)]. GFP is expressed 
concurrently with the shRNA and scramble vectors; thus both cell lines are GFP+. 
Jag1 protein was significantly decreased in the Jag1KD (GFP+) cell line, an 
effect that was stable for more than three weeks as determined by immunoblot 
analysis (Fig 2.5A).  Jag1 mRNA expression was also reduced by 63% while the 
related ligand Jag2 showed no statistically significant change (Fig 2.5B). The 
concurrent suppression of the Notch target gene Hes1 is consistent with a Jag1-
dependent activation of Notch signaling in ACC cells. 
 
Jag1 has a Non-cell-autonomous Effect on ACC Cell Proliferation 
 To analyze the effect of Jag1 knockdown on proliferation in Y1 cells, the 
MTS viability assay was utilized. While no difference in proliferation was 
observed between Scramble (GFP+) and Jag1KD (GFP+) cells when plated at 
low density (10% confluence, Fig 2.5C), Jag1KD (GFP+) cells showed a 32% 
reduction in proliferation when plated at a higher concentration (40% confluence, 
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Fig 2.5D). These data confirm that Jag1 exerts an effect on ACC cell proliferation 
in a density-dependent manner. Furthermore, immunoblot analysis revealed a 
reduction in Proliferating Cell Nuclear Antigen (PCNA), a marker of proliferation, 
in the Jag1KD (GFP+) cell lysates compared to Scramble (GFP+), while 
Cleaved-Caspase-3 (Clv-Csp-3), a marker of apoptosis, was not detected in 
either cell line (Figure 2.9A and data not shown). These data confirm that a loss 
of Jag1 protein inhibits the proliferation of Y1 cells. Predicated on the assumption 
that Jag1 acts through Notch receptors on adjacent cells, it would be expected to 
influence proliferation in a non-cell-autonomous manner consistent with the 
density dependence observed.  
 In light of recent data that suggest additional Notch receptor-independent 
biological functions of Jag1 and the related Notch ligands DLL1 and DLL3 within 
the cells in which they are expressed (cell-autonomous) [25, 43, 44], a co-culture 
system was designed utilizing FACS analysis to further interrogate the 
hypothesis that Jag1 acts in a non-cell-autonomous manner in ACC cells. 
Jag1KD (GFP+) or Scramble (GFP+) Y1 cell lines were grown in combination 
with wildtype Y1 cells expressing dsRedII [wildtype Y1 (Red+)] (Fig 2.6A). 
Wildtype Y1 (Red+) cells were cultured with Scramble (GFP+) or Jag1KD (GFP+) 
in two different ratios: 90% Red+ / 10% GFP+ or 10% Red+ / 90% GFP+ (Fig 
2.6B). The former condition (90% Red+ / 10% GFP+) assessed the ability of 
Jag1KD (GFP+) [relative to the Scramble (GFP+)] cells to proliferate upon 
receiving Jag1 inputs from wildtype Y1 (Red+) while the latter condition (10% 
Red+ / 90% GFP+) interrogates the effect of decreased Jag1 input to wildtype Y1 
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(Red+) cells. To guarantee sufficient cellular interactions, cells were initially 
plated at high density (70% confluence by Day 2, Fig 2.6B). To assure all cells 
could be analyzed at the same time at the end of the four day time course, the 
same initial concentration of cells were plated four days prior to analysis for Day 
4, three days prior to analysis for Day 3, etc (Fig 2.6A). Cell number for each 
FACS-sorted Red+ and GFP+ populations was determined at each time point 
and relative proliferation of the populations is presented as a percentage change 
in these cell numbers from Day 1 (Fig 2.6A). 
 To examine the hypothesis that Jag1 functions in a non-cell-autonomous 
manner, the following mixing experiment was performed. In the 90% Red+ / 10% 
GFP+ ratio, Jag1KD (GFP+) cells were cultured with an abundance of wildtype 
Y1 (Red+) cells expressing high amounts of Jag1, thus Jag1KD (GFP+) cells 
should be able to receive an abundance of Jag1 signaling inputs from 
neighboring wildtype Y1 (Red+) cells (Left panel, Fig 2.6B). Under these 
conditions, wildtype Y1 (Red+) cells show no relative change in proliferation 
whether cultured with Scramble (GFP+) and Jag1KD (GFP+) cells. This is 
expected since wildtype Y1 (Red+) cells are most likely receiving Jag1 inputs 
predominantly from other wildtype Y1 (Red+) cells (Top panel, Fig 2.6C, Fig 2.7). 
Importantly, no difference in the proliferation of Scramble (GFP+) and Jag1KD 
(GFP+) cells are observed under these co-culture conditions (Bottom panel, Fig 
2.6C, Fig 2.7). These data indicate that the Scramble (GFP+) and Jag1KD 
(GFP+) cells are capable of receiving Jag1 inputs from wildtype Y1 (Red+) cells 
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and, hence, proliferate normally supporting the hypothesis that Jag1 has a non-
cell-autonomous effect (Fig 2.7). 
 To further test the hypothesis that Jag1 acts in a non-cell-autonomous 
manner on adjacent cells, wildtype Y1 (Red+) cells were cultured with Jag1KD 
(GFP+) or Scramble (GFP+) cells at the ratio of 10% Red+ / 90% GFP+ (Right 
panel, Fig 2.6B). Under these conditions, wildtype Y1 (Red+) cells receive a 
majority of signaling input from GFP+ (Scramble or Jag1KD) cells.  Specifically, 
the wildtype Y1 (Red+) cells receive numerous Jag1 inputs from Scramble 
(GFP+) cells and reduced Jag1 inputs from the Jag1KD (GFP+) cells (Right 
panel, Fig 2.6B, Fig 2.7). Under these conditions, wildtype Y1 (Red+) cells show 
a 23% reduction in proliferation at Day 2 and a 27% reduction in proliferation at 
Day 3 (when co-cultured with Jag1KD (GFP+) cells (Top panel, Fig 2.6D). The 
Jag1KD (GFP+) cells also exhibit a maximal 35% reduction at Day 4  (Bottom 
panel, Fig 2.6D) consistent with the assumption that they are receiving the 
majority of signaling inputs from neighboring Jag1KD (GFP+) cells.  
 In summary, wildtype Y1 (Red+) cells proliferate less well when co-
cultured with 90% Jag1KD (GFP+) cells suggesting that a decrease of Jag1 
inputs results in retarded Y1 cell growth. Jag1KD (GFP+) cells remain competent 
to receive Jag1 inputs from wildtype Y1 (Red+) cells as reflected in the increased 
proliferation of the Jag1KD (GFP+) cells grown in the presence of 90% wildtype 
Y1 (Red+) cells. Jag1KD (GFP+) cells proliferated less well in the co-culture 
containing 90% Jag1KD (GFP+) cells suggesting that the decrease in Jag1 
inputs results in retarded Jag1KD (GFP+) cell growth. Together, the co-culture 
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studies indicate that Jag1 enhances ACC cell proliferation in a non-cell-
autonomous manner. See experimental model in Fig 2.7.  
 
Inhibition of Notch-Dependent Transcription Reduces ACC Cell Proliferation 
 The non-cell autonomous enhancement of ACC cell proliferation by Jag1 
is consistent with a Notch receptor-dependent process. As such, an inhibition of 
Notch-dependent transcription should phenocopy the Jag1 knockdown in a cell-
autonomous manner. Notch-dependent transcription is initiated by a ternary 
complex of the basally-repressive CSL, active signaling molecule NICD, and 
transcriptional coactivator MAML(1-4) [13, 14]. An engineered peptide sequence 
derived from Maml1, which has a dominant-negative effect on all Notch-
dependent transcription by competing for the endogenous Maml proteins and 
preventing their binding to NICD and CSL [29, 30] was utilized [DNMaml (GFP+): 
expresses GFP fusion protein of amino acids 13-74 of Maml1, Control (GFP+): 
expresses GFP]. Stable cell lines expressing either DNMaml or the Control 
construct were generated and RNA was isolated and analyzed by QPCR. In 
DNMaml (GFP+) cells, the canonical Notch target gene Hes1 and the putative 
target Cdkn1a are reduced by 64% and 43% respectively (Fig 2.8A).  Two 
unrelated but highly expressed genes in Y1 cells, Ctnnb1 (β-catenin) and Sf1 
(steroidogenic factor 1) were unaffected, consistent with a specific inhibition of 
Notch target genes in the DNMaml (GFP+) cell line.  
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 Since DNMaml inhibits Notch-dependent transcription, we hypothesized 
that DNMaml (GFP+) cells would have a reduced ability to proliferate when 
compared to Control (GFP+) cells. Employing the MTS viability assay to assess 
proliferation, DNMaml (GFP+) cells plated at 40% confluence showed a 37% 
reduction in proliferation when compared to Control (GFP+) cells (Fig 2.8B). 
Furthermore, immunoblot analysis revealed a reduction in PCNA protein level in 
DNMaml (GFP+) cell lysates compared to Control (GFP+), while Clv-Csp-3 was 
undetectable and the protein level of Cleaved-Caspase-6 (Clv-Csp-6), another 
marker of apoptosis, was unchanged (Fig 2.9B). 
 While Jag1 functions non-cell-autonomously to influence ACC cell 
proliferation, DNMaml targets downstream Notch signaling and should have a 
cell-autonomous effect on proliferation. To directly address this supposition, a 
similar co-culture study was performed using a 50% wildtype Y1 (Red+) / 50% 
Control (GFP+) or DNMaml (GFP+) ratio. Wildtype Y1 (Red+) cells co-cultured 
with either Control (GFP+) or DNMaml (GFP+) cells maintain robust proliferation 
(Left panel, Fig 8C). No statistically significant difference in Hes1 expression was 
observed on Day 4 in wildtype Y1 (Red+) cells cultured with GFP+ (Control or 
DNMaml) cells indicating DNMaml is not affecting Notch signaling in adjacent 
wildtype Y1 (Red+) cells (Right panel, Fig 2.8C). Conversely, DNMaml (GFP+) 
cells cultured with wildtype Y1 (Red+) cells exhibit a 34.3% reduction in 
proliferation when compared to Control (GFP+) cells cultured with wildtype Y1 
(Red+) cells (Left panel, Fig 2.8D). Hes1 mRNA was reduced 71.34% in 
DNMaml (GFP+) versus Control (GFP+) cells at Day 4 (Right panel, Fig 2.8D). 
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These data indicate DNMaml is acting specifically in DNMaml (GFP+) cells. 
Together with the Jag1 co-culture studies, these data support a Jag1 dependent 
activation of Notch signaling in ACC that can be targeted at the level of ligand 
(presenting cell) or receptor (receiving cell) to inhibit ACC cell proliferation.  
 
Notch receptor antibodies inhibit Notch target gene expression in Y1 cells while 
γ-secretase.inhibitors have no effect 
 Next, we asked whether Jag1-dependent activation of Notch signaling 
required γ-secretase complex mediated cleavage of the intracellular domain of 
the Notch receptor and the resultant generation and release of the active NICD 
[13, 14]. γ-secretase inhibitors, such as Dapt and Compound E, have been 
shown to be effective in inhibiting canonical Notch signaling in numerous 
systems [45], such as the MOLT4 T-ALL cell line[46]. Y1 cells and MOLT4 cells 
(used as a positive control) were treated with either vehicle or 100µM of DAPT 
and harvested for protein and mRNA analysis after 24h (Fig 2.10A, B). As 
expected, a loss of NICD protein and Hes1 expression was oberserved in the 
MOLT4 cell line with DAPT treatment. However, we surprisingly did not see loss 
of NICD or reduction in Hes1 expression in DAPT-treated Y1 cells or Y1 cells 
treated with an additional γ-secretase inhibitor, Compound E (γ-secretase 
inhibitor-XXI) (Fig 2.10C, D). Because NICD release from the Notch receptor is 
required for Notch pathway activation, we then chose to directly inhibit the Notch 
receptors using inhibitory Notch antibodies. These antibodies have previously 
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been shown to stabilize the negative regulatory region (NRR) of the Notch 
receptors and prevent S2 cleavage, a critical step in activation of Notch 
receptors[14, 38]. Treatment of Y1 cells with 80ng of either Notch1 or Notch2 
antibody revealed a significant decrease in Hes1 mRNA expression after 4h but 
not 24h (Fig 2.10C). Treatment with both Notch antibodies resulted in a 
significant decrease in Hes1 expression after 4h and 24h. These results are 
consistent with ligand-dependent Notch receptor cleavage and release of NICD 
in Y1 cells. 
 
JAG1 expression is correlated with increased aggressiveness of ACC 
 JAG1 is upregulated in ACC and acts through canonical Notch signaling to 
enhance density-dependent ACC cell proliferation. To determine whether 
elevated JAG1 mRNA expression levels in human ACC correspond to an 
increase in cancer aggressiveness, tumor stage and grade (as assessed by 
mitotic rate) were examined in the 33 ACC samples used in the microarray 
analysis. JAG1 mRNA expression levels correlated with advanced stage (r=0.35; 
p=0.04) and with mitotic rate (r=0.40; p=0.02) (Fig 2.11A, B). Specifically, JAG1 
expression was increased 1.67 fold (p=0.05) in late stage ACC (Stage III and IV) 
compared to early stage ACC (Stage I and II) (Fig 2.11A). Our previous 
microarray has shown strong correlations between KI67 and Topoisomerasse 2A 
(TOP2A) expression, two markers of proliferation that are highly upregulated in 
ACC, and immunohistochemical staining for Ki67 and Top2a protein [39]. We 
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identified a positive correlation of JAG1 expression with KI67 expression (overall 
correlation r=0.62, p<0.0001) and TOP2A (overall correlation r=0.69, p<0.0001) 
(Fig 2.11C, D). These data are consistent with the significant role of JAG1 in 
ACC cell proliferation and advanced stage of disease. 
 
Discussion 
 The Notch ligand JAG1 mRNA and protein are upregulated in 
adrenocortical carcinoma (ACC). JAG1 upregulation can be modeled in the Y1 
mouse ACC cell line that expresses Jag1, Notch receptors, and downstream 
signaling molecules. Y1 cells exhibit density-dependent Notch activation. Jag1 
enhances cell proliferation through activation of canonical Notch signaling as 
shown through knockdown and co-culture experiments. Inhibition of Notch 
signaling at the level of ligand (Jag1KD) or post receptor signaling (DNMaml), 
results in similar inhibition of cell proliferation. Analysis of clinical data indicates 
Jag1 expression correlates with both Grade and Stage of ACC supporting a role 
of JAG1-dependent Notch activation in ACC.  
 JAG1 upregulation has been observed in several cancers such as breast 
and prostate cancer where it facilitates proliferation and metastasis [24, 47]. In 
breast cancer, JAG1 is correlated with poor prognosis and lower survival rates in 
women with late stage, aggressive cancer [20-22]. Mechanistically, JAG1 has 
been shown to induce expression of cylinD1 in prostate cancer [23], enhance the 
  83 
number of cancer cells in S-phase [48], and facilitate proliferation in Wnt1-
transformed breast epithelial cells [49, 50].  
In addition to Notch ligands, Notch receptors Notch2 and Notch3 may be 
concomitantly upregulated in ACC. Upregulation of Notch2 receptors has been 
reported in several other cancers [51, 52] including gastric cancer, where an 
upregulation of Jag1 has also been observed [17, 53].  Notch2 does not show a 
positive correlation to JAG1 expression, which suggests that Notch2 and JAG1 
upregulation may be independent events. In contrast, expression of one Notch3 
probe set exhibits a positive correlation to JAG1 expression. Similarly, in lung 
cancer, JAG1 and Notch3 are upregulated in addition to enhancing proliferation 
of lung cancer cells, an effect that appears to be Notch3 dependent [54, 55].  
However, the stoichiometry of Notch receptor-ligand binding in adrenal tumors 
cells is unknown. The lack of a consistent upregulation amongst all Notch 
receptor probe sets suggests that in order to accommodate the upregulation of 
JAG1 observed in late stage ACC, a concomitant upregulation of Notch receptors 
may not be required.  
Furthermore, the Notch target gene Hey1 is upregulated in ACC and its 
expression is positively correlated to JAG1 expression while the related Notch 
target gene Hes1 does not. It is interesting that Hes1 appears to be Jag1-
mediated Notch target in Y1 cells but may not in human tumor.  It is possible that 
a unique set of Notch-regulated target genes is distinct in each of these systems. 
The full complement of genes that are regulated by Notch signaling in ACC is 
unknown and may include a plethora of non-canonical targets and/or the 
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expression profile of Notch-regulated genes may be distinct to each individual 
tumor. 
While the canonical mechanism by which Jag1 mediates cellular effects in 
numerous systems is through its binding to the Notch receptors and activation of 
downstream signaling [11-14], Jag1 and the other Notch ligands may also have 
receptor independent roles [25, 43, 44]. Overexpression of Jag1 has been shown 
to cell-autonomously induce transformation of RKE cells independent of Notch 
receptors but dependent on intracellular interaction between the cytoplasmic tail 
of Jag1 and Affadin, a cell adherens junction protein [25]. Furthermore, Jag1 and 
DLL1 are able to be processed by the γ-secretase complex to release 
intracellular signaling fragments [43]. In this report, knockdown of Jag1 in mouse 
adrenocortical cancer cells employing specific shRNAs resulted in a density-
dependent reduction in proliferation. Co-culture experiments of normal Y1 cells 
with either Jag1KD or Scramble cell lines tested whether Jag1 has a cell-
autonomous or non-cell-autonomous effect. Jag1KD cells were competent to 
proliferate provided they received sufficient Jag1 signaling inputs from adjacent 
cells. Cells receiving diminished Jag1 inputs from Jag1KD cells did not proliferate 
as well as cells receiving inputs from control (Scramble) cells. These data 
indicate Jag1 does not have a cell-autonomous effect but instead mediates 
adrenal cancer cell proliferation by binding to and activating Notch receptors on 
adjacent cells. The similar cell-autonomous reduction of growth following 
inhibition of Notch-dependent transcription utilizing a dominant negative version 
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of the transcriptional coactivator Maml1 supports the conclusion that Jag1 effects 
ACC cell proliferation in a non-cell-autonomous manner. 
 Of obvious interest is the molecular mechanism of JAG1 upregulation in 
human ACC. It is informative that Wnt and Notch are known to synergize in a 
variety of developmental systems such as the ear where Jag1 acts to mediate 
some of the effects of downstream Wnt/β-Catenin signaling on the formation of 
the otic placode [56]. Moreover, JAG1 has been shown to be a direct target of β-
catenin in the epidermis where Notch signaling is required for β-catenin mediated 
melanoma formation [57, 58]. A synergistic effect between Notch and Wnt on 
tumorigenesis is also seen in breast and colon carcinoma where JAG1 is 
upregulated in both of these cancers [15, 20, 49, 59].  
 Whether the Notch and Wnt pathways interact in ACC is unknown. While 
repression of Notch-dependent transcription had no effect on β-catenin (Ctnnb1) 
expression in the DNMaml experiments (Fig 8A), it remains unknown if Wnt 
activation synergizes or activates various components of the Notch pathway. 
Nuclear β-catenin has been observed in both benign ACAs and malignant 
ACCs[5-9] as well as the known ACC cell lines H295A. Whether JAG1 is a 
downstream target of Wnt signaling in ACC is currently unknown. Additionally, 
mouse models of ACC in which β -catenin is constitutively active have been 
recently reported[10, 60]. It would be informative to examine whether β -catenin 
activation has an effect on Jag1 and other Notch factor expression in this model. 
Furthermore, conditional knockout of Jag1 in Wnt/β-catenin-induced colorectal 
tumors results in a reduction in tumor size when compared to tumors in which 
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Jag1 expression is not genetically altered [61]. Understanding the mechanism of 
JAG1 upregulation in ACC will be an important area of investigation.  
The correlation of high JAG1 levels with high grade and late stage ACC in 
the current study is provocative and suggests JAG1 upregulation is a later event 
in ACC. Activating mutations of β-catenin have been identified in both ACA and 
ACC which suggests activation of the Wnt pathway may be a crucial step in 
initiation of adrenocortical tumorigenesis [5-10, 60]. Furthermore, the insulin-like 
growth factor (IGF) pathway ligand, IGF2, has been shown to be the most 
differentially upregulated gene in ACC [26, 62]. Taken together, these data 
suggest the Wnt activation concurrent with upregulation of IGF2 may be critical 
molecular events required for ACC development. Recently, our group has shown 
that a mouse model in which Wnt and IGF pathways are overactivated develops 
adrenal tumors that manifest as histopathologically more advanced than tumors 
in mice where only Wnt or IGF pathways are perturbed[60]. These data support 
the hypothesis that Wnt and IGF pathways synergize to drive adrenocortical 
tumor growth. However, the lack of penetrance of ACC formation in these mice 
argues against the IGF and Wnt pathways as sufficient to induce progression to 
bona fide ACC. The correlation of JAG1 expression with late stage ACC 
suggests its upregulation may be a molecular event that antecedes that 
activation of Wnt and IGF pathways. Targeting Jag1-mediated Notch signaling 
may be a potential novel target for therapy, possibly in tandem with inhibition of 
IGF and/or Wnt signaling. 
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Figure 2.1:  JAG1 is upregulated in human ACC. A. Heatmap of Affymetrix 
U133A 2.0 Plus oligonucleotide array representing Notch ligand genes. Normal 
Adrenal (NL), n=10, Adrenocortical Adenoma (ACA) n=22, Adrenocortical 
Carcinoma (ACC), n=33). Scale is indicated. B. Dot plot of two JAG1 and JAG2 
probe sets. Each dot indicates one tissue sample. Lines indicate mean 
expression levels. JAG1 #1: ACC vs NL * p=4x10-6, ACC vs ACA # p=7x10-12), 
JAG1 #2: ACC vs NL** p=1x10-6, ACA vs NL ## p=2x10-11), JAG2 #1: ACC vs 
NL *** p=6x10-4, ACC vs ACA ### p=4x10-4), JAG2 #2: ACC vs NL **** 
p=5.3x10-3, ACC vs ACA #### p=3x10-4). C. QPCR analysis of mRNA from 
randomly selected human samples (NL: n=5, ACA: n=5, ACC: n=10) for JAG1 
and JAG2. Each data point represents an average of triplicate determinations. D. 
Correlation of Log-transformed JAG1 QPCR expression data (from Fig 1C) with 
the corresponding JAG1 (probe set #2) microarray data (from Fig 1B) (r=0.874, 
p=5x10-7) and JAG2 QPCR data with JAG2 (probe set #1) microarray data 
(r=0.545, p=0.013). E. Top panel: Immunoblot analysis of 5µg of protein lysates 
from randomly selected human adrenal samples (NL: n=5, ACA: n=5, ACC: 
n=10). Blots were probed for Jagged1 and β-actin used as a loading control. 
Molecular weights are indicated. Bottom panel: Quantification of Immunoblots. 
Jag1 protein was normalized to β-Actin and then to NL sample #06. The average 




























































































































































































































































































































































































Figure 2.2:  Notch receptors exhibit variable expression in human ACC. A. 
Dot plot of two Notch1, Notch2 and Notch3 and one Notch4 probe sets. Each dot 
indicates one tissue sample. Lines indicate mean expression levels. Normal 
Adrenal (NL), n=10, Adrenocortical Adenoma (ACA) n=22, Adrenocortical 
Carcinoma (ACC), n=33. Notch2 #1: * ACC vs ACA p = 0.01, # ACA vs NL 
p=0.003. Notch3 #2: ** ACC vs ACA p=0.008, ACC vs NL ## p=0.01. B. 
Correlation of JAG1 (Probe Set #2) microarray expression with Notch2 (Probe 
Set #1), overall correlation r=0.056, p=0.656, and Notch3 (Probe Set #2), overall 
correlation r=0.29, p=0.021. C. QPCR analysis of mRNA from randomly selected 
human samples (NL: n=5, ACA: n=5, ACC: n=10) Notch2. Each data point 















































































































































































































































Figure 2.3:  Notch target genes are upregulated in human ACC. A. Dot plot 
of two Hes1 and Hey1 probe sets. Each dot indicates one tissue sample. Lines 
indicate mean expression levels. Normal Adrenal (NL), n=10, Adrenocortical 
Adenoma (ACA) n=22, Adrenocortical Carcinoma (ACC), n=33. Hey1 #1: * ACC 
vs ACA p = 0.0004, # ACC vs NL p=0.0007. Hey1 #2: ** ACC vs ACA, p=0.0008, 
ACC vs NL ## p=0.005. B. Correlation of JAG1 (Probe Set #2) microarray 
expression with Hey1 (Probe Set #1), overall correlation r=0.34, p=0.0053, and 
Hey1 (Probe Set #2), overall correlation r=0.34, p=0.0054. C. QPCR analysis of 
mRNA from randomly selected human samples (NL: n=5, ACA: n=5, ACC: n=10) 















































































































































































































































































Figure 2.4: The Y1 mouse ACC cell line exhibits active Notch signaling. A. 
Immunoblot analysis of 10µg of protein lysate from WT mouse adrenal (Adrenal), 
mouse ACC cell line (Y1), and human ACC (H295, RL251) cell lines for Jag1, 
Notch1, Notch2, and NICD. β-actin is used as loading control. B. Efficiency-
corrected ΔCT QPCR method of triplicate samples used to quantify the 
expression of the 5 Notch ligands in Y1 cells (* JAG1 vs JAG2, p=0.00001). 
Representative experiment of three repetitions. C. Immunofluorescent 
colocalization of Jag1 with Notch1, Notch2, and Hes1 in Y1 cells. D. Luciferase 
constructs for the Notch reporter, which contains 4 CSL binding sites, and 
Control reporter, which the 4 CSL sites are mutated. E. Top panel: Immunoblot 
analysis of 10µg of protein lysate from Y1 cells treated with 5mM EDTA or 
vehicle (PBS) for 6h. Blots were probe for NICD and β-actin, used as loading 
control. Bottom panel: Luciferase assay of triplicate samples of Notch 
(4xwtCBF1Luc; pJH23A) and Control (4xmtCBF1Luc; pJH25A) reporter in Y1 
cells treated with 5mM EDTA or vehicle for 6h. Luciferase expression is 
normalized to p-RL-TK Renilla expression (EDTA, Notch: * vs EDTA, Control 
p=0.004, # vs Vehicle, Notch p=0.0039). Representative experiment of three 
repetitions. F. Immunoblot analysis of 10µg of protein lysate from H295A cells 
treated with 2.5mM and 5mM EDTA or vehicle (PBS) for 6h. Blots were probe for 
NICD and β-actin, used as loading control. G. Top panel: Immunoblot analysis of 
NICD levels of 10µg of protein lysates of Y1 cells grown at 10%, 25%, 50%, 90% 
confluence. β-actin is used as loading control. Bottom panel: Luciferase assay of 
triplicate samples of Notch and Control reporter expression (normalized to 
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Renilla) in Y1 cells grown at 10% (low density) and 90% (high density) 
confluence (High density, Notch: * vs High density, Control p=0.00003, # vs Low 











































































































































































Figure 2.5: Jag1 knockdown in Y1 cells inhibits proliferation in a density-
dependent manner. A. Immunoblot analysis of protein lysates from stable cell 
lines expressing shRNAs for either Scramble or Jag1 [Scramble (GFP+) and 
Jag1KD (GFP+) respectively]. Blots were probed for Jag1 and β -actin, used as 
loading control. B. QPCR analysis of mRNA from Scramble (GFP+) and Jag1KD 
(GFP+) stable cell lines analyzed by the ΔΔCT method, and normalized to β-actin 
[Scramble (GFP+) vs Jag1KD (GFP+): * Jag1 p=0.0002, # Hes1 p=0.001]. 
Representative experiment of five repetitions.  Absorbance values obtained from 
MTS viability assay on cell lines [Scramble (GFP+) vs Jag1KD (GFP+)] plated at 
(C.) 10% confluence at Day 1 and growth to 35% confluence by Day 4 and (D.) 
40% confluence at Day1 and growth to 85% by Day 4, Scramble (GFP+) vs 
Jag1KD (GFP+) at Day 4, * p=0.0045. Each data point represents an average ± 






















































































































































Figure 2.6: Jag1 enhances ACC proliferation in a non-cell-autonomous 
manner. A. Schematic indicating experimental design. dsRedII+ (normal Y1) 
cells were co-cultured with GFP+ (Scramble or Jag1KD) cells in ratios 90% 
Red+/ 10% GFP+, or 10% Red+/ 90% GFP+. Initial combined cell number (Red+ 
plus GFP+) was 150,000 cells and triplicate wells were plated. The same initial 
plating was used for each time point and cells were plated 4 days from harvest 
for the Day 4 timepoint, 3 Days from the harvest for the Day 3 timepoint, etc. 
Harvested cells were analyzed by FACS. 10,000 sorted cells were counted for 
each timepoint and the number of Red+ and GFP+ determined for each count. 
The percentage change in cell number from Day 1 was determined by the 
formulas indicated and based on the 10,000 cells counted for each time point. B. 
Immunocytochemical images of the two different co-culture conditions at Day 2. 
C. Top panel: The percentage change of Red+ cells from Day 1 for each 
timepoint in the 90% Red+/10% GFP+ condition. Bottom panel: The percentage 
change of GFP+ cells from Day 1 for each timepoint in the 90% Red+/10% GFP+ 
condition. D. Top panel: The percentage change of Red+ cells from Day 1 for 
each timepoint in the 10% Red+/90% GFP+ condition (* p<0.03).  Bottom panel: 
The percentage change of GFP+ cells from Day 1 for each timepoint in the 10% 
Red+/90% GFP+ condition. Scramble (GFP+) vs Jag1KD (GFP+) at Day 2, 3, 
and 4, * p<0.0001). Each bar represents an average ± SD of 3 determinations. 
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Figure 2.7: A model of Jag1-Notch signaling occurring in co-culture 
experiments. A visual representation of the types of signaling occurring between 
normal Y1 (Red+) and Scramble/Jag1KD (GFP+) cells in the two co-culture 
conditions. Jag1KD cells (Right panel) are able to receive Notch inputs (90/10) 
but not send them (10/90). Red+ and Scramble cells (Left panel) are both able to 


















































Figure 2.8: DNMaml suppression of Notch-dependent transcription reduces 
Y1 cell proliferation to a similar degree as Jag1 Knockdown. A. QPCR of 
mRNA from stable cells lines expressing either Control (GFP+) or DNMaml 
(GFP+) constructs analyzed using the ΔΔCT method and normalized to β -actin 
[Control (GFP=) vs DNMaml (GFP+): Hes1 * p=0.0001, Cdkn1a # p=0.02]. B. 
Absorbance values obtained from MTS viability assay on cell lines [Control 
(GFP+) vs DNMaml (GFP+), * p<0.0001]. Each data point represents an average 
± SD of 6 determinations. Representative experiment of four repetitions. Co-
culture of 50% normal Y1 cells (Red+) and either 50% Control (GFP+) or 50% 
DNMaml cells (GFP+). Initial combined cell number (Red+ plus GFP+) was 
150,000 cells and triplicate wells were plated. The same initial plating was used 
for each time point and cells were plated 4 days from harvest for the Day 4 
timepoint, 3 Days from the harvest for the Day 3 timepoint, etc. Harvested cells 
were analyzed by FACS. 10,000 cells were counted for each timepoint and the 
number of Red+ and GFP+ determined for each count. The percentage change 
in cell number from Day 1 was determined by the formulas indicated (y-axis) and 
based on the 10,000 cells counted for each time point, C. Left panel: The 
percentage change of Red+ cells from Day 1 for each timepoint. Right panel: 
mRNA was harvested from Red+ cells at the Day 4 timepoint for the Control and 
DNMaml co-culture. Hes1 expression was determined by the ΔΔCT method and 
normalized to β-actin. β-catenin. D. Left panel: The percentage change of GFP+ 
cells from Day 1 for each timepoint [Control (GFP+) vs DNMaml (GFP+), * 
p<0.0001, # p=0.06]. Right panel: mRNA was harvested from GFP+ cells at the 
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Day 4 timepoint for the Control and DNMaml co-culture. Hes1 expression was 
determined by the ΔΔCT method and normalized to β -actin (* p=0.0066). Each 
bar represents an average ± SD of 3 determinations. Representative experiment 























































































































































































































































































Figure 2.9: Jag1 knockdown or inhibition of Notch-dependent transcription 
in Y1 cells reduces proliferation but has no effect on apoptosis. A. 
Immunoblot analysis of protein lysates from stable cell lines expressing shRNAs 
for either Scramble or Jag1 [Scramble (GFP+) and Jag1KD (GFP+) respectively]. 
Blots were probed for Jag1, Proliferating Cell Nuclear Antigen (PCNA) and β-
actin, used as loading control. B. Immunoblot analysis of protein lysates rom 
stable cells lines expressing either Control (GFP+) or DNMaml (GFP+) 
constructs. Blots were probed for PCNA, Cleaved-Caspase-6 (Clv-Casp-6) and 











































Figure 2.10: Notch receptor antibodies inhibit Notch target gene expression 
in Y1 cells. A. Immunoblot analysis of 15µg of protein lysate from MOLT4 and 
Y1 cells treated with vehicle (DMSO) or 100µM, 500µM DAPT for 24h. Blots 
were probed for NICD and β-actin, used as loading control. B. QPCR analysis for 
Hes1 of mRNA in triplicate from vehicle or 100µM treated Y1 and MOLT4 cells 
analyzed by the ΔΔCT method, and normalized to β -actin. Representative of 
triplicate experiments. MOLT4, Vehicle vs 100µM DAPT, * p < 0.0001 C. 
Immunoblot analysis of 15µg of protein lysate from Y1 cells treated with 100, 250, 
400, and 500ng of Compound E or vehicle (DMSO) for 24h. Blots were probed 
for NICD and β-actin, used as loading control. D. QPCR analysis for Hes1 of 
mRNA in triplicate from vehicle or 100, 250, 400, and 500ng Compound E 
treated Y1 cells analyzed by the ΔΔCT method, and normalized to β -actin. 
Representative of triplicate experiments. E. QPR analysis of Hes1 mRNA in 
triplicate from vehicle, 80ng anit-Notch1 antibody, anti-Notch2 antibody, or 
combination of both antibodies after 4h and 24h treatments. Average of duplicate 
experiments.  Notch1Ab, 4h or Notch2Ab, 4h vs Vehicle, 4h * p < 0.002, 













































































































































































































Figure 2.11: JAG1 expression is highest in aggressive, highly proliferating 
ACC. A. Correlation of JAG1 expression (base-2 log transformed) for stage in 
ACCs (n=33). 19 Stage I + II vs 14 Stage III + IV p=0.0551, overall correlation 
r=0.35, p=0.04. B. Correlation of JAG1 expression (base-2 log transformed) with 
mitotic rate (base-2 log transformed). Overall correlation r=0.40, p=0.02. C. 
Correlation of JAG1 expression (base-2 log transformed) with KI67 expression 
(base-2 log transformed) across all human adrenal samples used in the 
microarray data set. Overall correlation r = 0.62, p<0.0001. D. Correlation of 
JAG1 expression (base-2 log transformed) with TOP2A expression (base-2 log 
transformed) across all human adrenal samples used in the microarray data set. 















































































































































































































































































Primer Name Species Forward Sequence Reverse Sequence
JAG1 Human 5'­tgccaagtgccaggaagt­3' 5'­gccccatctggtatcacact­3'
JAG2 Human 5'­tgggactgggacaacgatac­3' 5'­atgcgacactcgctcgat­3'
Beta­Actin Human 5'­tgacaggatcgagaaggaga­3' 5'­cgctcaggaggagcaatg­3'
JAG1 Mouse 5'­gaggcgtcctctgaaaaaca­3' 5'­acccaagccactgttaagaca­3'
JAG2 Mouse 5'­tcctcctgctgctttgtgat­3' 5'­tgtcaggcaggtcccttg­3'
DLL1 Mouse 5'­acagaggggagaagatgtgc­3' 5'­ccctggcagacagattgg­3'
DLL3 Mouse 5'­tcgtacgtgtgcccttcc­3' 5'­tgctctctccaggtttcaatg­3'
DLL4 Mouse 5'­aggtgccacttcggttacac­3' 5'­gggagagcaaatggctgata­3'
HES1 Mouse 5'­acaccggacaaaccaaagac­3' 5'­cgcctcttctccatgatagg­3'
CDKN1A Mouse 5'­tccacagcgatatccagaca­3' 5'­ggacatcaccaggattggac­3'
SF1 Mouse 5'­tccagtacggcaaggaagac­3' 5'­ctgtgctcagctccacctc­3'
CTNNB1 Mouse 5'­gcagcagcagtttgtgga­3' 5'­tgtggagagctccagtacacc­3'
Beta­Actin Mouse 5'­ctaaggccaaccgtgaaag­3' 5'­accagaggcatacagggaca­3'
Table 1: QPCR Primers
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Antibody Name Species Use Company Catalog # 
Jagged1 (C­20) Goat IB, ICC, OD  Santa Cruz Sc­6011
Hes1 Rabbit ICC Millipore AB5702
Cleaved Notch1 (Val1744) Rabbit IB Cell Signaling 2421
Notch1 (C­20) Goat ICC Santa Cruz Sc­6014
Notch2 (25­255) Rabbit ICC Santa Cruz Sc­5545
btan20 (Notch1) Rat IB Iowa DHSB na
C651.6DbHN (Notch2) Rat IB Iowa DHSB na
Beta­Actin Mouse IB Sigma A­5411
Anti­Goat IRDye 800 CW Donkey OD LICOR 926­32214
Anti­Mouse IRDye 680 Goat OD LICOR 926­32220
Anti­Goat IgG HRP Rabbit IB Thermo Scientific 31433
Anti­Mouse IgG HRP Goat IB Pierce 31434
Anti­Rabbit IgG HRP Goat IB Pierce 31462
Anti­Rat HRP Goat IB Pierce 31475
Anti­Rabbit Dylight 549 Goat ICC Jackson ImmunoResearch
Anti­Goat Dylight 549 Rabbit ICC Jackson ImmunoResearch 305­505­045




























































































































































































Chapter 3: The Role of Notch signaling in Normal 
Adrenal Biology 
Abstract 
The adrenal gland is an endocrine organ composed of the embryologically and 
functionally distinct cortex, which secretes steroid hormones, and medulla, which 
secretes catecholamine hormones. Notch signaling is a highly conserved 
developmental signaling pathway that has been shown to be involved in 
development and/or maintenance of numerous organ systems. Notch signaling 
has been implicated in the development of sympathetic ganglia, which are of the 
same embryonic lineage of the adrenal medulla, but Notch has never been 
considered in chromaffin cell development and/or function. We have identified 
Notch ligands, receptors, and canonical target genes Hes1 and Hes5 are 
expressed in the adrenal medulla. Inhibition of canonical Notch signaling in TH+ 
cells, a marker of all chromaffin cells, results in an upregulation of expression of 
the catecholamine biosynthetic enzyme TH while overactivation of Notch 
signaling in TH+ cells results in a reduction in expression of the epinephrine-
synthesizing enzyme PNMT. Furthermore, inhibition of canonical Notch signaling 
in Sf1+ cells had no effect on the function or histology of the adrenal cortex, but 
did manifest with abnormalities in the ovary. These data suggest Notch signaling 
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may be important in modulating the production of catecholamine hormones from 
the adrenal medulla and may have implications for pheochromocytoma, a tumor 
derived from chromaffin cells of the adrenal medulla.  
 
Introduction 
The adrenal glands are endocrine organs located superior to the kidneys that are 
responsible for the coordination of the mammalian stress response. The 
mesoderm-derived cortex secretes the glucocorticoids cortisol and corticosterone 
while the neuroectoderm-derived medulla secretes catecholamine hormones [1]. 
The adrenal medulla is primarily involved in mitigation of the “fight or flight” 
through secretion of the catecholamine hormones Epinephrine and to a lesser 
extent, Norepinephrine [2]. 
 Chromaffin cells of the adrenal medulla are derived from the 
sympathadrenal (SA) lineage, a population of progenitors cells originating from 
the neural crest (NC) that give rise to sympathetic ganglia, the adrenal medulla, 
and extra-adrenal paraganglia (e.g “the organ of Zuckerkandl”) [3]. Many studies 
have elucidated the role of a host of transcription factors in SA specification and 
chromaffin cell development, such as Mash1 [4], Phox2B [5], Phox2A [6], dHand 
[7], Gata3 [8], and Sox protein[9] (See review [10]. Signaling pathways such as 
the bone morphogenic protein (BMP) pathway have also been identified as 
crucial for determination of SA fate and migration [11, 12]. Furthermore, 
glucocorticoid signaling from the adrenal cortex to the adrenal medulla has been 
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implicated in the maturation of epinephrine-secreting (adrenergic) chromaffin 
cells through induction of the epinephrine-synthesizing enzyme 
phenylethanolamin-N-methyltansferase (PNMT) [13-15]. However, the role of 
signaling pathways mitigating migration of chromaffin progenitors into the adrenal 
primordia and specifying chromaffin cell fate during development in the post-
migratory adrenal environment have not been considered. 
 The Notch signaling pathway is an evolutionarily conserve pathway that 
has been implicated in the development and/or maintenance of numerous organ 
systems [16-18]. Canonical Notch signaling occurs between interaction between 
transembrane ligands and receptors expressed on adjacent cells that culminates 
in the release of the active signaling molecule, the cleaved Notch intracellular 
domain. In the avian embryo, Notch pathway members are expressed in the 
neural ectoderm adjacent the neural tube and have been implicated in 
specification of the NC lineage [19, 20]. Furthermore, Notch signaling may 
suppress differentiation of sympathetic neurons, which suggest a selective role of 
Notch signaling in SA development [21]. However, the function of the Notch 
pathway in chromaffin cell development has not been considered. 
 We report that active Notch signaling occurs in chromaffin progenitors of 
the fetal medulla and in mature chromaffin cells of the adult medulla. Tissue-
specific inhibition of canonical Notch signaling in TH+ cells results in an 
upregulation of TH mRNA and proteins. Furthermore, overactivation of Notch 
signaling in TH+ cells reduces the expression of PNMT in chromaffin cells. As 
shown through inhibition of Notch signaling in Sf1+ cells, Notch signaling appears 
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to be dispensable for the overall development and maintenance of the adrenal 
cortex. These data provide evidence for a putative role of Notch signaling in 
modulating chromaffin cell expression of catecholamine synthesizing enzymes.  
 
Materials and Methods 
Mouse lines 
All mouse lines including Hes1+/GFP and Hes5+/GFP[22], TH+/Cre[23], Sf1+/Cre,[24] 
R26R-Tom+/EGFP[25], R26R+/DNMaml[26], and R26R+/NICD[27] have been previously 
characterized. TH+/Cre and R26R+/NICD were obtained from the Jackson 
Laboratory (Bar Harbor, ME). Hes1+/GFP and Hes5+/GFP lines were generously 
provided by Dr. Linda Samuelson (University of Michigan, Ann Arbor, MI). 
R26R+/DNMaml was generously provided by Dr. Ivan Maillard (University of 
Michigan, Ann Arbor, MI). 26R-Tom+/EGFP was generously provided by Dr. 
Andrzej Dlugosz (University of Michigan, Ann Arbor, MI). Some lines were bred 
to homozygosity as indicated. For timed breedings, embryos were staged by 
designating noon of the day in which the copulatory plug was detected as E0.5. 
Genders of embryos was determined with SRY genotyping of the yolk sac. Lines 
were maintained on mixed genetic backgrounds. For a complete list of 
genotyping primers, see Table 3.1. All animal protocols were approved by the 
University of Michigan Institutional Animal Care and Use Committee.  
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Immunohistochemical and immunofluorescent analysis 
 Adrenals were harvested and fixed in 4% paraformaldehyde for 1.5-4hrs 
(depending on the age of the animals and the type of cross employed) at 4°C. 
Tissues were dehydrated in graded ethanol solutions (50% and 70%) followed by 
paraffin embedding. 6µm sections were cut using a microtome. Sections were 
sequentially rehydrated by two 5min incubations in each xylenes, 95% and 100% 
ethanol, and water. For histological analysis, slides incubated directly in 
hematoxylin and eosin (H&E) solutions for 2min each and then dehydrated in the 
opposite manner as described above. Paramount was used to coverslip the 
slides. 
For immunofluorescent stains, dehydration of tissue sections was 
performed as described above. Antigen retrieval was performed by boiling 
rehydrated sections in 10mM  (pH6) or 5mM (pH2) sodium citrate buffer for 
10min followed by 20min cooling step. Sections were washed 1X in phosphate-
buffered saline (PBS) for 2min then blocked with in 3% milk in PBS solution for 4-
5hrs at 4°C (or 1hr at room temperature). Slides were washed 1X in PBS then 
incubated in primary antibodies diluted in 0.3% milk in PBS overnight at 4°C. For 
a complete list of primary and secondary antibodies used in this chapter, see 
Table 3.3. Slides were then washed three times for 5min in PBS and then 
incubated in immunofluorescnt secondary antibodies diluted in 0.3% milk in PBS 
for 2hrs at room temperature. Slides were then washed one time in PBS then 
counterstaned with Dapi (1:1000) for 5min. Three additional 5min PBS washes 
were performed. Cover slips were applied and images obtained as previously 
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described[28, 29].  For some sections, detection of primary antibodies was 
performed with a chromogenic approach using diaminobenzidine (Sigma, St. 
Louis, MO). 
 
Quantitative real time-PCR (QPCR) analysis 
 Adrenals were homogenized and then RNA isolated with the RNAeasy 
mini kit (Qiagen, Valencia, CA). cDNA was generated using the iScript cDNA 
synthesis kit (Bio-Rad laboratories, Hercules, CA). QPCR experiments were 
performed as previously described[28, 29]. A comprehensive list of QPCR 
primers can be found in Table 3.2. Analysis was conducted with either the 
efficiency-corrected Δ CT method of the ΔΔ CT method as indicated[30]. 
Expression of mRNA was normalized to β -actin. Statistical analyses of QPCR 
experiments were made using student’s T-test. 
 
Immunoblot analysis 
 Analysis of protein lysates from homogenized adrenal glands was 
performed as previously described[28]. Analysis of protein lysate was conducted 
as described but blocking was done in Odyssey Blocking buffer (Licor, Lincoln, 
NE), secondary antibodies were used were odyssey IRdyes (Table 3). 




Canonical Notch target genes Hes1 and Hes5 are expressed in the adrenal 
medulla. 
 Notch signaling has previously been reported in sympathetic ganglia, 
which are of the same developmental lineage as chromaffin cells [21]. In order to 
identify whether active Notch signaling was also occurring in chromaffin cells of 
the adrenal medulla, we employed a transgenic reporter mouse approach. Hes1 
and Hes5 are two bHLH genes that have been shown to be direct targets of 
canonical Notch signaling in a variety of systems [16].  Two transgenic mice in 
which EGFP expression is driven by a 2.5kb region of the Hes1 promoter 
(Hes1+/GFP) or by a 0.76kb region of the Hes5 promoter (Hes5+/GFP) have 
previously been reported (Fig 3.1A, See Fig 3.1 for a description of all mouse 
lines employed in this chapter) [22]. Both lines of Hes transgenic mice were bred 
to homozygosity in order to maximize detection of the GFP signal (Hes1GFP/GFP 
and Hes5GFP/GFP, respectively).  
Immunofluorescent detection of GFP protein revealed Hes1 promoter 
activity throughout the adrenal medulla at birth (P0) and throughout adult life up 
to 23wks of age (later time points were not examined) (Fig 3.2A). Tyrosine 
Hydroxylase (TH), the first enzyme in catecholamine biosynthesis that is 
expressed in every chromaffin cell of the adrenal medulla, and Steroidogenic 
Factor 1 (Sf1), a transcription factor required for steroidogensis that is expressed 
in every adrenocortical cell, were used to delineate the adrenal medulla and 
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cortex respectively (Fig 3.2A, B) [3, 24, 31]. Hes1 expression was detected 
exclusively in the adrenal medulla as indicated by costains with TH (Fig 3.2A, top 
row). While a vast majority of TH+ cells appeared to be GFP+, some GFP- cells 
were detected suggesting Hes1 is not expressed at the same level in every 
chromaffin cell. 
 Hes5 expression was also detected in the adrenal medulla as indicated by 
immunofluroescent detection of GFP protein in Hes5GFP/GFP transgenic mice. In 
contrast to Hes1, in neonatal mice (P5), Hes5 expression was not detected 
throughout the adrenal medulla but was localized to discrete clusters of TH+ cells 
(Fig 3.2B, top row). In adult mice at 4wks of age, similar cell clusters were 
detected but they seemed to localize towards the periphery of the medulla (Fig 
3.2B, bottom row). 
 Notch signaling has been implicated in the formation of the neural crest 
but its role in SA progenitor cells during development has not been delineated 
[20, 32]. To investigate the role of Notch signaling in chromaffin progenitors of 
the SA lineage, we performed timed breedings using Hes1GFP/GFP and 
Hes5GFP/GFP mice (Fig 3.3). We examined embryos for Hes1 expression at E12.5, 
the approximate time point at which chromaffin progenitors begin to invade the 
adrenal primordial [1, 33]. As expected, robust TH expression was detected 
ventral to the dorsal aorta (DO), where SA progenitors are believed to mature 
(Fig 3.3A, top row). GFP protein was also detected throughout the same region 
but appeared to exhibit a broader expression pattern. However, the adrenal 
primordial was not detected in these sections.  
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We examined animals in which we can detect TH+ cells migrating into the 
adrenal primordial, which are presumed to be chromaffin cell progenitors (Fig 
3.3A, bottom two rows) [10]. Many of the TH+ cells appeared to concurrently 
express GFP but an additional population of GFP+ cells lacked TH expression. 
These GFP+/TH- cells seemed to reside within the adrenal primordial itself but 
since GFP costaining with Sf1 was not performed, the identity of this population 
could not be confirmed. Chromaffin progenitors have previously been observed 
to invade the adrenal primordia from the dorsal side (the “head” of the adrenal 
primordia) [34]. When examined at higher magnification, the population of TH+ 
cells that was oriented dorsal of the adrenal primordial was almost entirely GFP+, 
suggesting that chromaffin progenitors engage in active Notch signaling prior to 
invasion of the adrenal anlage (Fig 3.3A, bottom two rows, far right panels, 400X 
magnification). 
Next, we considered the activity of Notch signaling in post-migratory 
environment of the developing fetal adrenal gland. In E14.5 Hes5GFP/GFP mice, we 
detected Hes5+ (GFP+) cells throughout the adrenal medulla and many of these 
cells colocalized with TH (Fig 3.3B). Similar to the expression pattern observed 
in neonatal mice, Hes5 expression was not detected in every TH+ cell. In 
contrast, in E16.5 Hes1GFP/GFP mice, GFP expression was detected throughout 
the adrenal medulla, presumably in every TH+ cell, but this was not confirmed 
since costaining with TH was not performed at this time point (Fig 3.3C). Taken 
together, these data indicate that canonical Notch target genes Hes1 and Hes5 
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are expressed in TH+ chromaffin cells of the adult and developing adrenal 
medulla, which suggests that active Notch signaling is occurring in these cells. 
 
Notch pathway ligand and receptors are expressed in the adrenal medulla 
 The expression of Hes1 and Hes5 strongly indicates that active Notch 
signaling is occurring in the medulla but since Hes1 transcription can be initiated 
through other pathways [35, 36], we wondered if Notch ligands and receptors are 
concomitantly expressed in the adrenal medulla. First, we performed relative 
expression QPCR using the efficiency-correct ΔCT method to determine the 
relative quantities of the five canonical Notch ligands (Jag1/2, Dll1/3/4) in male 
and female mice between P0 and 50wks of age (Fig 3.4A) [37]. At every time 
point for both genders, Jag1 was the predominant ligand present while Jag2 and 
Dll4 were also robustly detected but were present in lower quantities than Jag1. 
Dll1 and Dll3 were expressed at considerably lower levels compared to the other 
three ligands. Next, using the same QPCR data but analyzed using the ΔΔCT 
method, we determined that change in expression of the Notch ligands over time 
in both male and female mice (Fig 3.4B). Despite variation at some of the time 
points, the expression of Notch ligands was constant throughout adult mouse life.  
To confirm the QPCR data, immunofluorescent detection of Dll4 (Fig 
3.4C) and Jag1 (Fig 3.4D) was performed. Because the expression profile of 
Notch ligands was virtually identical between males and females, we decided to 
only consider male mice. Dll4 was detected in discrete clusters of TH+ cells 
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throughout the adrenal medulla at 3, 23 and 50wks of age (Fig 3.4C). In contrast, 
Jag1 expression was detected throughout the medulla. The broader expression 
pattern of Jag1 compared to Dll4 may account for the increased quantity of Jag1 
compared to Dll4. Interestingly, Jag1 was also detected in the subcapsule of the 
adrenal cortex, a region believed to contain adrenal progenitor cells (Fig 3.4D, 
bottom panel) [38, 39]. These data prove that Notch ligands are expressed in the 
adrenal medulla concurrent with Hes1 and Hes5 expression. 
In addition to the five canonical ligands, the identification of a host of non-
canonical ligands has been reported (for review, see [37]). One of the most 
studied is the Dlk1, a transmembrane protein that shares a remarkable degree of 
structural similarity to the canonical Notch ligands [40]. Expression of Dlk1 has 
previously been identified in chromaffin progenitors pre- and post-migration into 
the adrenal primordia, as well as chromaffin cells of the adult medulla [41, 42]. As 
expected, immunofluorescent detection of Dlk1 was detected throughout the 
adrenal medulla (Fig 3.5). Dlk1 expression was detected in every TH+ cell of the 
fetal medulla at E14.5, when migration of chromaffin progenitors into the fetal 
adrenal is complete, (Fig 3.5A) and in the postnatal medulla (Fig 3.5B). Dlk1 
expression was maintained throughout adult life (Fig 3.5C). These data confirm 
the previous reports that Dlk1 is expressed in fetal and adult chromaffin cells. 
Therefore, in addition to the canonical ligands Jag1 and Dll4, Dlk1 may be 
involved in activation and/or modulation of Notch activity in the adrenal medulla. 
The presence of the Notch ligands in medulla provides another lines of 
evidence that active Notch signaling is occurring in chromaffin cells. We 
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extended our analysis to the four Notch receptors that have been identified in 
mice (Fig 3.6) [16, 17]. Using the same mRNA samples and analysis as 
described in Fig 3.4, we analyzed the relative quantities of the Notch receptors in 
male and female mice between 0 and 50wks of age (Fig 3.6A). At early time 
point in both genders, Notch2 was the predominant ligand expressed while at 
later time points, Notch1 appeared to be more robustly expressed than Notch2 in 
male mice. Notch1 and Notch2 were expressed at comparable quantities in later 
time points in female mice, concurrent with increased detection of Notch4. At 
every time point in both genders, Notch3 expression was lower than the other 
three receptors.  
As with the analysis of the ligands, the QPCR data were reanalyzed to 
examine changes in expression of the Notch receptors over time (Fig 3.6B). In 
male mice, Notch2-4 expression remained constant over time while Notch1 
expression increased, which confirmed the greater relative quantities of Notch1 
detected in the previous analysis. In female mice, expression of Notch1-3 
remained constant over time while an upregulation of Notch4 was identified, 
which confirmed the increased quantities of Notch4 detected in later time points 
in the previous analysis. Despite the increased in Notch4 expression in older 
mice, Notch1 and Notch2 appear to be the predominant receptors expressed in 
both male and female mice, and we therefore focused our analysis on these two 
receptors. 
To confirm the QPCR data, immunofluroescent detection of Notch1 and 
Notch2 was performed in male mice (Fig 3.6C, D). Both Notch1 and Notch2 
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exhibited a broad expression pattern throughout the adrenal medulla. Notch2 
expression colocalized with TH confirming that Notch2 is expressed in TH+ 
chromaffin cells of the medulla. However, the expression of Notch2 was not the 
same in every TH+ cells (Fig 3.6C, left panel). Several TH+, Notch2- cells were 
detected at higher magnification, which suggests that activation of Notch2-
dependent signaling is not the same in all chromaffin cells (Fig 3.6C, bottom 
panel). In contrast, Notch1 expression appeared similar in most cells, although 
the intensity of the Notch1 signal seemed greater at the periphery of the adrenal 
medulla. These data taken together with the Notch ligand and target gene 
expression studies, confirm that active Notch signaling is occurring in chromaffin 
cells of the adrenal medulla. However, the specific type of Notch-ligand 
interactions occurring between chromaffin cells cannot be precisely determined 
from these studies. 
 
Inhibition of canonical Notch signaling in TH+ chromaffin cells results in an 
upregulation of TH expression 
 We have shown that Notch receptors, ligands, and canonical target genes 
are expressed in the TH+ chromaffin cells of the adrenal medulla. In order to 
interrogate the function of Notch in these cells, we took advantage of Cre-Lox 
technology to inhibit canonical Notch signaling in TH+ cells. This was 
accomplished using the TH+/Cre line in which Cre recombinase is knocked into the 
3’ UTR of the endogenous TH gene [23] (Fig 3.1B). This mouse has previously 
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been reported to target 100% of TH+ cells of the adrenal medulla [23]. In order to 
test the recombination efficiency of this line, we crossed the TH+/Cre line to the 
R26R-Tom+/EGFP line (Fig 3.7). The R26R-Tom+/EGFP line is a dual fluorescent 
reporter mouse that expresses the Tomato fluorescent protein in the absence of 
Cre, but in the presence of Cre, the Tomato gene is excised and EGFP is 
expressed instead (Fig 3.1C) [25]. Therefore, TH+ cells that express Cre 
recombinase should also express EGFP. However, as determined by 
immunofluroescent detection of GFP protein, only a portion of adrenal medullary 
cells in TH+/Cre:R26R-Tom+/EGFP mice expressed GFP (Fig 3.7, right panels). As a 
control, no GFP was detected in TH+/+:R26R-Tom+/EGFP mice (Fig 3.7, left panels). 
Two different TH+/Cre mice were crossed to two different R26R-Tom+/EGFP mice 
but the result was the same for both TH+/Cre lines. The lack of complete 
recombination in every TH+ cell conflicts with the previously reported expression 
in the adrenal medulla of this mouse [23].  
Despite the mosaic expression pattern of the Cre, we used the TH+/Cre line 
to inhibit canonical Notch signaling in TH+ cells by crossing it to the R26R+/DNMaml 
line. R26R+/DNMaml is a Rosa26 locus knock-in mouse that employs a NeoSTOP 
cassette upstream of the DNMaml-EGFP fusion protein, a peptide derived from 
amino acids 13-74 of Maml1 that has been shown to inhibit all downstream 
canonical Notch signaling [26, 43] (Fig 3.1D). In the presence of Cre 
recombinase expression, the NeoSTOP cassette is excised and the DNMaml 
peptide is expressed [26].   
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We analyzed the TH+/Cre:R26R+/DNMaml mice through immunofluorscent 
detection of various histological markers of chromaffin cells (Fig 3.8). 
TH+/Cre:R26R+/DNMaml were born in normal mendelian ratios and exhibited no 
gross defects in histology of neonatal adrenal glands as determined by Sf1 and 
TH expression, as well as the cytoskeletal protein neuronal class III-β-tubulin 
(TuJ1) (Fig 3.8A). The expression of phenylethanolamine-N-methyltransferase 
(PNMT), an enzyme that catalyzes the conversion of norepinephrine to 
epinephrine and is expressed in virtually every chromaffin cell of the mouse 
medulla, was unchanged in TH+/Cre:R26R+/DNMaml mice compared to 
TH+/+:R26R+/DNMaml mice [3, 44, 45]. Dopamine transporter 1 (DAT1), a 
membrane transporter protein responsible for reuptake of catecholamine 
hormones back into chromaffin cells, also exhibited no differences in expression 
[2, 46]. At P20, no differences in Sf1/TH and PNMT expression were also 
detected (Fig 3.8C). Furthermore, expression of 20α-hydroxysteroid 
dehydrogenase (20αHSD), a marker of the fetal adrenal cortex, was unchanged, 
which suggests that there is no effect on the development of the adrenal cortex.  
We wondered if doubling the dosage of the DNMaml gene would be 
sufficient to compensate for the ineffectual Cre recombination, but no changes in 
TH, PNMT, or TuJ1 were detected in TH+/Cre:R26RDNMaml/DNMaml mice compared to 
TH+/+:R26R+/DNMaml mice (Fig 3.8B). Since Notch signaling is known to modulate 
its own expression, we examined the expression of Dll4 at P20 but observed no 
changes. These data suggest that inhibition of Notch signaling in a subset of 
chromaffin cells has no effect on the gross histology of the adrenal medulla or 
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cortex. This may be a consequence of the lack of complete penetrance of the 
TH+/Cre line in mediating recombination. Older animals have also not been 
considered histologically. 
To further examine the molecular phenotype of the medulla in the Notch 
inhibition mice, we performed QPCR analysis on adrenals from P12 
TH+/Cre:R26RDNMaml/DNMaml and TH+/+:R26R+/DNMaml mice (Fig 3.9A). We identified 
a statistically significant downregulation in Hes1 in both animals analyzed and a 
statistically significant downreulation of Hes5 in one animal, which suggests that 
Notch signaling is indeed being inhibited. Of particular interest, we saw 
significant upregulation in TH expression. Furthermore, modest but statistically 
significant increases in expression of noradrenaline tranporter 1 (NAT1), a 
catecholamine reuptake transporter in the same family as DAT1 [46, 47], and 
chromogranin A, a peptide hormone secreted concurrently with catecholamine 
hormones [48], were identified. We also observed downregulations in DAT1 and 
the catechol-O-methyl transferase (COMT), an enzyme involved in conversion of 
catecholamines to excretable metabolites [49]. TH upregulation was confirmed 
by immunoblot analysis of adrenals from 3wks TH+/+:R26R+/DNMaml, 
TH+/Cre:R26R+/DNMaml and TH+/Cre:R26RDNMaml/DNMaml animals (Fig 3.9B). 
Quantification of the immunoblots identified increased levels of TH protein in 2/3 
of the animals analyzed (Fig 3.9C). Taken together, these data suggest inhibition 
of Notch signaling may alter the catecholamine production, but not the gross 
histology, of chromaffin cells. Additional animals need to be analyzed in order to 
verify these results. 
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Overactivation of Notch signaling in TH+ cells results in a reduction of PNMT 
expression in chromaffin cells 
 To complement the Notch inhibition studies, we constitutively activated 
canonical Notch signaling in TH+ cells using the R26R+/NICD line (Fig 3.10). 
R26R+/NICD is a Rosa26 locus knock-in mouse that employs a NeoSTOP cassette 
upstream of a sequence encoding a constitutively active NICD followed by an 
IRES-EGFP (Fig 1E) [27].  In the presence of Cre recombinase expression, the 
NeoSTOP cassette is excised and the NICD is expressed.  
No differences in the gross histology of P0 and P20 adrenals from 
TH+/Cre:R26R+/NICD compared to TH+/+:R26R+/NICD was observed, as determined 
by immunofluorescent detection of Sf1 costained with TH and TH costained with 
20αHSD (Fig 3.10A).  However, at 6wks, the expression of PNMT, which 
normally exhibits a broad pattern of expression throughout the adrenal medulla, 
was detected as a salt-and-pepper expression pattern (Fig 3.10B). PNMT- cells 
were clearly detected in TH+/Cre:R26R+/NICD compared to TH+/+:R26R+/NICD mice, 
which suggests that the population of epinephrine-secreting adrenergic 
chromaffin cells is reduced with overactivation of Notch signaling. The expression 
of DAT1 and TuJ1 showed no difference at this time point.  
This observation was confirmed through QPCR analysis of adrenals from 
8wks TH+/Cre:R26R+/NICD and TH+/+:R26R+/NICD mice (Fig 3.10C). We identified a 
statistically significant increase in Hes1 and Hes5 expression in one animal 
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analyzed concurrent with a downregulation of PNMT. Upregulations in aromatic 
amino acid decarboxylase (AADC) and dopamine-β-hydroxylase (DBH), two 
enzymes that precede PNMT in epinephrine synthesis [2], were also observed. 
Taken together, these data suggest overactivation of Notch signaling may reduce 
PNMT expression and drive chromaffin cells towards a noradrenergic fate. 
However, only one of the two animals analyzed exhibited this phenotype by 
QPCR. These observations need to be confirmed with a larger sample size.  
 
Canonical Notch signaling is dispensable for development of the adrenal cortex 
but not for the ovary 
 Canonical Notch signaling does not appear to be occurring the adrenal 
cortex (Fig 3.2) although Jag1 expression can be detected in the subcapsular 
region (Fig 3.4D). We have previously reported an upregulation of Jag1 in 
adrenocortical carcinoma, which mediates a non-cell autonomous effect on cell 
proliferation through canonical Notch signaling (Chapter 2 of this thesis and[50]). 
To interrogate whether or not active Notch signaling is occurring in the normal 
adrenal cortex, we employed the Sf1+/Cre line crossed to the R26R+/DNMaml line. 
The Sf1+/Cre is a transgenic mouse driving Cre expression from the complete Sf1 
promoter (Fig 1F) [24]. We have previously reported the successful function of 
this line in our hands [29]. 
 To assess the function of Notch in Sf1+ cells, we analyzed adrenals from 
male and female Sf1+/Cre:R26R+/DNMaml and Sf1+/Cre:R26RDNMaml/DNMaml mice (Fig 
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3.11 and Fig 3.12). Histological analysis revealed no gross differences in the 
adrenals from Sf1+/Cre:R26R+/DNMaml and Sf1+/Cre:R26RDNMaml/DNMaml mice 
compared to Sf1+/+:R26R+/DNMaml mice for both females (8-65wks of age, Fig 
3.11A) and males (18-50wks of age, Fig 3.12A). Immunofluorescent analysis of 
TH and Cyp11b1, a key enzyme in cortisol synthesis, in 35wks females, revealed 
no gross differences in medulla and cortex respectively (Fig 3.11C). Sf1 
costained with TH at 50wks of age confirmed the lack of apparent phenotype in 
both females (Fig 3.11D) and males (Fig 3.12B). We have previously shown that 
β-catenin is required for adrenocortical development and maintenance and its 
expression is restricted to the subcapsular zone [29]. We analyzed β -catenin 
expression at 50wks in females (Fig 3.11D) and males (Fig 3.12B) but did not 
identify any differences in expression, which suggests that adrenocortical 
stem/progenitor function is unaffected. Finally, QPCR analysis of adrenals from 
35wks Sf1+/Cre:R26R+/DNMaml, Sf1+/Cre:R26RDNMaml/DNMaml, and Sf1+/+:R26R+/DNMaml 
confirmed that Notch target genes were not affected nor histological markers Sf1 
and TH (Fig 3.11B). Taken together, these data show that Notch signaling is 
dispensable for development and maintenance of the adrenal cortex. 
 In addition to the adrenal cortex, Sf1 expression also is required for the 
gonads [51]. Indeed, the Sf1+/Cre line has previously been shown to successfully 
target Sf1+ cells of the gonad in addition to the adrenal cortex[24]. One 
explanation for the lack of phenotype in Sf1+/Cre:R26R+/DNMaml mice could be lack 
of recombination but this is clearly not the case as ovaries collected from these 
mice exhibit severe abnormalities (Fig 3.13). Histological analysis of ovaries from 
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Sf1+/Cre:R26R+/DNMaml and Sf1+/Cre:R26RDNMaml/DNMam females reveals multi-oocytic 
follicles and the development of blood-filled cysts compared to normal, single-
oocytic follices (Fig 3.13A). Interestingly, ovaries from younger mice appear 
histologically similar but the phenotype becomes severe by 30wks of age. There 
did not appear to be difference in expression of Sf1 in ovaries from 
Sf1+/Cre:R26RDNMaml/DNMaml compared to Sf1+/+:R26R+/DNMaml females, which 
suggest the defect may lie in maturation and/or release of follicles during 
ovulation (Fig 3.13B). 
 
Overactivation of Notch signaling in Sf1+ cells results in stochastic adrenal 
aplasia 
 Because we have reported an activation of Notch signaling in adrenal 
tumors, we also overactivated Notch signaling in Sf1+ by crossing the Sf1+/Cre 
line to the R26R+/NICD line (Fig 3.14). Interestingly, adrenal aplasia was identified 
in Sf1+/Cre:R26R+/NICD  mice, as determined by whole-organ analysis of the urinary 
tract (Fig 3.14A, B). Adrenal progenitor cells appeared to migrate the proper 
location, superior to the kidneys, but were severely reduced in size. About 50% 
of animals died at birth, most likely due to a loss of hormones secreted from the 
adrenal cortex and/or medulla. Immunofluorescent analysis revealed a stochastic 
effect on the Sf1+ cortical cells and TH+ medullary cells. (Fig 3.14C). In some 
cases, the aplastic adrenal appeared to be composed mostly of Sf1+ cells while 
in other animals, the aplastic adrenal was composed mostly of TH+ cells. 
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Because of the fact that Notch inhibition has no effect on the development of the 
adrenal cortex, strongly suggests that Notch is inactive in Sf1+ cells. Therefore, 
interpretation of the results in the Sf1+/Cre:R26R+/NICD  mice and was pursued 
further. Taken together with the Sf1+/Cre:R26R+/DNMaml studies, these data suggest 
that Notch signaling is dispensable for development of the adrenal cortex and 
may even be actively repressed. 
 
Discussion 
 Active Notch signaling is occurring in chromaffin cells of the adrenal 
medulla as determined by the expression of the canonical Notch target genes 
Hes1 and Hes5, the canonical Notch ligands Jag1 and Dll4, the noncanonical 
ligand Dlk1, and the Notch receptors Notch1 and Notch2. Hes1 and Hes5 
expression are also present in TH+ chromaffin progenitors pre- and post-invasion 
of the adrenal primordia. Inhibition of canonical Notch signaling does not result in 
gross histological changes in chromaffin cells but results in an upregulation of the 
catecholamine-synthesizing enzyme TH at the mRNA and protein level. In 
contrast, overactivation of Notch signaling in TH+ cells results in reduced 
expression of epinephrine-synthesizing enzyme PNMT, which suggests there 
may be reduction in the population of adrenergic chromaffin cells. Furthermore, 
inactivation of Notch signaling in Sf1+ cells has no effect on adrenocortical 
development or maintenance but results in severe abnormalities in the ovary. 
Overactivation of Notch signaling in Sf1+ cells results in adrenal aplasia. 
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 Chromaffin cells are derived from the SA lineage of the neural crest. In 
addition to the medullary chromaffin cells, the SA lineage gives rise to 
sympathetic ganglia and sites of extra-adrenal paraganglia such as the 
suprarenal ganglia and the fetal “organ of Zuckerkandl” [10]. While numerous 
transcription factors have been implicated in SA differentiation, the signals that 
define a chromaffin versus a sympathetic fate are ill defined. Furthermore, 
molecular signals that are required for chromaffin progenitor cell invasion into the 
adrenal primordial and maturation in the fetal adrenal environment are poorly 
understood. The observation that many Hes1+ (GFP+) cells that lack TH 
expression aggregate at the vicinity of the adrenal primordia is intriguing. It is 
unlikely that these TH-/GFP+ cells are Sf1+ fetal adrenocortical cells since we 
have demonstrated that canonical Notch signaling is dispensable for 
adrenocortical development. Several studies have suggested that some 
chromaffin progenitors that migrate into the adrenal primordial lack TH 
expression until post-migration [9, 52]. Therefore, Hes1 may define a population 
of pluripotent SA progenitors that is not committed to a chromaffin cell fate until 
after cessation of invasion of the adrenal primordia.  
Furthermore, the adrenal medulla has been analyzed in studies where 
transcription factors implicated in early SA progenitor differentiation, such as 
Mash1 and Phox2B, have been ablated. In Mash1 deficient mice, expression of 
downstream transcription factors dHand and Phox2A are not disrupted in a 
majority of chromaffin cells, which suggests a Mash1-independent population of 
chromaffin cells invade the adrenal medulla [4]. In contrast, in Phox2B deficient 
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mice, dHand and Phox2A were lost in a majority of chromaffin cells but Mash1 
expression was still detectable in some TH+ cells [5]. These studies suggest 
chromaffin progenitors dependent upon Mash1 are independent of chromaffin 
progenitors dependent on Phox2B. The developmental origin of these distinct 
populations and there relationship to SA progenitors of the sympathetic lineage is 
not clear. Taken together, these studies suggest that a single population of SA 
progenitors committed to a chromaffin cell fate may not invade the adrenal 
primordial. Notch signaling therefore may serve as a common signal for SA 
progenitors that express differential transcription factor profiles (i.e. Mash1 or 
Phox2B). 
Indeed, expression of the noncanonical Notch ligand Dlk1 has been 
identified in chromaffin progenitors prior to invasion of the adrenal anlage, during 
maturation of chromaffin cells in the fetal adrenal gland, and in fully differentiated 
adult chromaffin cells [41, 42, 53]. However, when we inhibited Notch signaling in 
TH+ cells, the adrenal medulla developed normally and there was no evidence 
that chromaffin cells were not differentiated. Two potential explanations for these 
results seem plausible. First, the lack of penetrance of the TH+/Cre suggests a 
majority of the SA progenitors are not being targeted and the remaining 
population may be sufficient for the development of the medulla. Second, as 
discussed above, a subpopulation of the chromaffin progenitor cells that invade 
the adrenal anlage may not express TH until after they have taken up residence 
within the fetal adrenal gland [9]. Therefore, inhibition of Notch signaling in TH+ 
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cells would have no effect on this population. Further studies are required to 
elucidate these possibilities. 
However, the role of Notch signaling in the SA lineage and chromaffin 
progenitors may be distinct from its function in mature chromaffin cells of the 
adult adrenal medulla. In our Notch inhibition studies, we identified an 
upregulation of TH mRNA and protein concurrent with upregulations in the 
message of NAT1 and ChrA and downregulations of COMT and DAT1. The 
observations that TH is upregulated and COMT is downregulated suggests an 
increase in catecholamine production may be occurring. The altered expression 
of the reuptake transporters DAT1 and NAT1 further supports this hypothesis but 
since both transporters can reuptake epinephrine and norepinephrine, the 
specific changes in catecholamine production cannot be determined from gene 
expression changes alone [46]. The possibility of changes in the catecholamine 
profile secreted from chromaffin cells in TH+/Cre:R26RDNMaml/DNMaml animals needs 
to be confirmed with analysis of circulating catecholamine levels and/or their 
metabolites (metanephrines) [54]. 
The proper dosage of Notch signaling may also be important in defining 
noradrenergic (norepinephrine-secreting) and adrenergic (epinephrine-secreting) 
chromaffin cell types. In our Notch overactivation studies we observed a loss of 
PNMT expression in 6wks TH+/Cre:R26R+/NICD animals as shown by 
immunfluorescent detection of PNMT protein and QPCR analysis of PNMT 
mRNA. These data suggest that an excess of Notch signaling may drive 
chromaffin cells towards a noradrenergic cell fate. However, this phenotype has 
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only been examined in adult mice and was not 100% penetrant amongst all 
animals analyzed, possibly due to the ineffectual TH+/Cre line. Additional studies 
of aged TH+/Cre:R26R+/NICD are required to confirm these observations. 
Separate from the observations in the adrenal medulla, we have shown 
that Notch signaling is dispensable for the development and maintenance of the 
adrenal cortex. In both male and female Sf1+/Cre:R26R+/DNMaml and 
Sf1+/Cre:R26RDNMaml/DNMam mice, the adrenal cortex and medulla formed normally. 
Furthermore, expression of the cortisol-synthesizing enzyme Cyp11b1 was 
unchanged in Notch inhibition mice. Additionally, expression of the Wnt pathway 
downstream effector β-catenin, which is believed to be involved in maintenance 
of adrenocortical stem/progenitors cells, was unchanged [29, 38, 39]. Conversely, 
overactivation of Notch signaling in Sf1+ cells resulted in adrenal aplasia, but 
since Notch signaling is not active in Sf1+ cells, the interpretation of these results 
is difficult. Taken together, these studies suggest an absence of Notch signaling 
in Sf1+ cells is required for adrenocortical development. 
Interestingly, ovaries in female Sf1+/Cre:R26R+/DNMaml and 
Sf1+/Cre:R26RDNMaml/DNMaml mice developed multi-oocytic follicles and blood-filled 
cysts. Previous reports have shown that Notch pathway genes are expressed in 
ovarian follicles and pharmacologic inhibition of Notch signaling results in 
reduced numbers of primordial follicles, precursors to follicles that develop with 
the onset of sexual maturity [55, 56]. Our studies further support the importance 
of Notch signaling in follicle development but, because our lab does not study the 
gonads, this hypothesis was not pursued. 
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The observations in the Notch overactivation studies may have implication 
for pheochromocytoma (PCC), a catecholamine-secreting neoplasm that is 
derived from adrenal medullary chromaffin cells [57, 58]. Several hereditary 
cancer syndromes have been identified that manifest in PCC. PCC develop in 
about 10-20% of the autosomal dominant von Hippel-Lindau (vHL) syndrome and 
these PCC primarily secrete norepinephrine [59, 60]. In contrast, PCC are 
detected in about 50% of patients with autosomal dominant syndrome multiple 
endocrine neoplasia type 2 (MEN2) and these PCC are primarily epinephrine-
secreting [60-62]. Gene expression profiling studies have identified an 
upregulation of Jag1 and Notch3 in vHL and sporadic norepinephrine-secreting 
PCC compared to MEN2 and sporadic epinephrine-secreting PCC [63]. 
Chromaffin cells in our Notch overactivation studies exhibit reductions in PNMT 
expression, which suggests that chromaffin cells in this model adopt a 
noradrenergic-like phenotype. Taken together, these data suggest an 
upregulation of Notch signaling in PCC may define an norepinephrine-favored 
catecholamine secretory profile. Furthermore, Notch signaling has been shown to 
be downregulated in malignant and recurring PCC, which suggests that Notch 
may confer a more differentiated phenotype in some PCC [64, 65]. These 
observations correlate with our identification of Notch ligand, receptor, and target 
gene expression in mature chromaffin cells. Targeting inhibition of Notch 
signaling may therefore have dual effects in PCC depending on the 
catecholamine secretory profile and the aggressiveness of the PCC tumor but 
further studies are needed to elucidate this potential therapeutic avenue. 
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Figure 3.1: Mouse lines. A. Transgenic Hes1+/GFP and Hes5+/GFP mice in which 
EGFP expression is driven by 2.5kb and 0.76kb of the Hes1 and Hes5 promoters, 
respectively. The SV(40) poly(A) signal is used for proper translation of EGFP. B. 
The TH+/Cre line is knock-in of IRES-Cre recombinase in the 3’ UTR of the mouse 
TH gene. Arrows indicate orientation of the Cre cassette. Triangles indicate Frt 
sites used for excision of the Neo cassette following selection of positive clones. 
C. The R26R-Tom+/EGFP line employs expression of Tomato protein driven by the 
pCA promoter and is a knock-in into the Rosa26 locus. In the presence of Cre 
recombinase expression, the Tomato cassette is excised (triangles indicate LoxP 
sites) and EGFP protein is expressed. D. The R26R+/DNMaml line employs a 
NeoSTOP cassette upstream of the DNMaml-EGFP fusion protein cassette and 
is knocked into the Rosa26 locus. In the presence of Cre recombinase, the 
NeoSTOP cassette is excised (triangles indicate LoxP sites) and the DNMaml 
protein is expressed. The Poly(A) sequence is indicated. E. The line employs a 
NeoSTOP cassette upstream of the NICD-IRES-EGFP cassette and is knocked 
into the Rosa26 locus. In the presence of Cre recombinase, the NeoSTOP 
cassette is excised (triangle indicate LoxP sites) and the NICD-IRES-EGFP 
protein is expressed. The Poly(A) sequence is indicated. F. The transgenic 
Sf1+/Cre uses a 111kb BAC clone which contains the complete Sf1 promoter and 
coding region (top panel). Cre recombinase is inserted into upstream of Sf1 
exons 2 and 3 (bottom panel). Four copies of the final Sf1-Cre BAC clone is 

























































































Figure 3.2: Canonical Notch target genes Hes1 and Hes5 are expressed in 
chromaffin cells of the adrenal medulla. A. Immunofluorescence of 
Hes1GFP/GFP male mice at P0, 4, 12, and 23 weeks of age for GFP (red) or GFP 
(red) co-stained with TH (green). Immunofluorescence for Sf1 (red) co-stained 
with TH (green) is used to indicate the adrenal cortex (c) and medulla (m). Dapi 
is used as counterstain. C.   Immunofluorescence of Hes5GFP/GFP male mice at P5 
and 4 weeks of age for GFP (red) or GFP (red) co-stained with TH (green). 
Immunofluorescence for Sf1 (red) co-stained with TH (green) are used to indicate 

















































Figure 3.3: Canonical Notch target genes Hes1 and Hes5 are expressed in 
chromaffin progenitor cells during development. A. Immunofluorescence of 
E12.5 Hes1GFP/GFP male mice for GFP (red) co-stained with TH (green). 
Immunofluorescence for Sf1 (red) co-stained with TH (green) are used to indicate 
the adrenal primordium (Ap) and Gonadal primordium (Gp). Images are oriented 
Doral (top) to ventral (bottom). Dorsal aorta: Do. Dapi is used as counterstain. B. 
Immunofluorescence of E14.5 Hes5GFP/GFP mice for GFP (red) co-stained with TH 
(green). The fetal adrenal gland (Fad) and kidney (K) are indicated. Dapi is used 
as counterstain. C. Immunofluorescence of E16.5 Hes1GFP/GFP mice for GFP (red). 
































































Figure 3.4: Notch ligands Jag1 and Dll4 are expressed in the mouse adrenal 
medulla. A. Efficiency-corrected ΔCT QPCR of mRNA in triplicate samples used 
to quantify the expression of the five Notch ligands in WT male (left panel; time 
points 0, 3, 7, 18, 40 and 50 weeks of age, n=1 for each time point) and Female 
(right panel; time points 0, 3, 8, 18, 27, 46 weeks of age, n=1 for each time point) 
mice. Normalized to β -actin. B. Relative expression QPCR of mRNA from 
triplicate samples for the five Notch ligands in WT male (left panel; time points 0, 
3, 7, 18, 40, 48, 50 weeks of age, n=1 for each time point) and WT female (right 
panel; time points 0, 3, 8, 18, 27, 31, 38, 46 weeks of age, n=1 for each time 
point) mice. Normalized to β -actin. C. Immunofluorescence of adrenal glands 
from male mice for Dll4 (red) or Dll4 (red) co-stained with TH (green) at 3, 12, 23, 
and 50 weeks of age. Dapi is used as counterstain. D. Immunofluorescence of 
adrenal glands from male mice for Jag1 (red) at 23 and 48 weeks of age. Dapi is 
























































































































































































































































Figure 3.5: The non-canonical Notch ligand Dlk1 is expressed in TH 
positive chromaffin cells. Immunofluorescence for Dlk1 (Red), TH (green) and 
Dapi (blue) as a counterstain at E14.5 (A.), P0 (B.), 18 and 27 weeks (C.) of age. 
The cortex (c) and medulla (m) are indicated in images where staining for TH 























































Figure 3.6: Notch receptors Notch1 and Notch2 are expressed in the mouse 
adrenal medulla. A. Efficiency-corrected ΔCT QPCR of mRNA in triplicate 
samples used to quantify the expression of the four Notch receptors in WT male 
(left panel; time points 0, 3, 7, 18, 40 and 50 weeks of age, n=1 for each time 
point) and Female (right panel; time points 0, 3, 8, 18, 27, 46 weeks of age, n=1 
for each time point) mice. Normalized to β-actin. B. Relative expression QPCR of 
mRNA from triplicate samples for the four Notch receptors in WT male (left panel; 
time points 0, 3, 7, 18, 40, 48, 50 weeks of age, n=1 for each time point) and WT 
female (right panel; time points 0, 3, 8, 18, 27, 31, 38, 46 weeks of age, n=1 for 
each time point) mice. Normalized to β-actin. C. Immunofluorescence of adrenal 
glands from male mice for Notch2 (red) or Notch2 (red) co-stained with TH 
(green) at 23 and 40 weeks of age. Dapi is used as counterstain. D. 
Immunofluorescence of adrenal glands from male mice for Notch1 (red) at 23 








































































































































































































































Figure 3.7: Targeting chromaffin cells of the adrenal medulla using TH+/Cre 
mouse line. Immunofluorescence for GFP (red) and TH (green) in TH+/+:R26R-
Tom+/EGFP (left panels) and TH+/Cre:R26R-Tom+/EGFP (right panels). Dapi is used 



















































Figure 3.8: Inhibition of canonical Notch signaling has no effect on the 
gross histology of the adrenal medulla.  A. Immunofluorescence analysis of 
adrenals from P0 TH+/+:R26R+/DNMaml and TH+/Cre:R26R+/DNMaml  male mice for Sf1 
(red) costained with TH (green), PNMT (red), DAT1 (red) and TuJ1 (red). Dapis 
is used as counterstain. B. Immunofluorescence analysis of adrenals from P12 
TH+/+:R26R+/DNMaml and TH+/Cre:R26RDNMaml/DNMaml  male mice for TH (green) 
costained with PNMT (red) and TuJ1 (red). Dapi is used as counterstain. C. 
Immunofluorescence analysis of adrenals from P20 TH+/+:R26R+/DNMaml and 
TH+/Cre:R26R+/DNMaml  male mice for Sf1 (red) costained with TH (green), PNMT, 
20αHSD (red) costained with TH(green), and Dll4 (red) costained with TH (green). 








































































































































































Figure 3.9: TH mRNA and protein is upregulated in TH+/Cre:R26R+/DNMaml mice. 
A. Relative expression QPCR (triplicate determinations) of mRNA from adrenals 
of P12 male TH+/+:R26R+/DNMaml (n=1) and TH+/Cre:R26RDNMaml/DNMaml (n=2) mice.  
ThCre/DNMaml/DNMaml #1 vs Wt/DNMaml * p<0.0001, ** p=0.03, 
ThCre/DNMaml/DNMaml #2 vs Wt/DNMaml, # p<0.004, ## p=0.05. B. 
Immunoblot analysis of adrenals from TH+/+:R26R+/DNMaml (n=1), 
TH+/Cre:R26R+/DNMaml (n=2), and TH+/Cre:R26RDNMaml/DNMaml (n=2) male mice at 
3wks of age. C. Quantification of the immunblot analysis for TH protein levels 









































































































































Figure 3.10: Overactivation of canonical Notch signaling reduces the 
population of adrenergic chromaffin cells. A. Immunofluorescence analysis of 
Th+/+:R26R+/NICD  and TH+/Cre:R26R+/NICD male mice at P0 and P20 for Sf1 (red) 
costained with TH (green), 20αHSD costained with TH (green) and Dll4 (red) 
costained with TH (green). Dapi is used as counterstain. B. Immunofluorescence 
analysis of mice 6wks of age for TH (green), PNMT (red), DAT1 (red), and TuJ1 
(red). Dapis is used as counterstain. C. Relative expression QPCR (triplicate 
determinations) of mRNA from adrenals of 8wks Th+/+:R26R+/NICD (n=2) and 
TH+/Cre:R26R+/NICD (n=2) male mice. * ThCre/NICD #1 vs Wt/NICD #1, p<0.02, # 
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Figure 3.11: Inhibition of canonical Notch signaling in Sf1 positive cells has 
no effect on the adrenal glands of female mice. A. Histology of adrenals from 
Sf1+/+:R26R+/DNMaml, Sf1+/Cre:R26R+/DNMaml, Sf1+/Cre:R26R+/DNMaml and 
Sf1+/Cre:R26RDNMaml/DNMaml female mice between 18 and 50wks of age. B. 
Relative expression QPCR analysis (triplicate determinations) of mRNA from 
adrenals of 35wk Sf1+/+:R26R+/DNMaml (n=1), Sf1+/Cre:R26R+/DNMaml (n=2), and 
Sf1+/Cre:R26RDNMaml/DNMaml (n=2) female mice. Immunofluorescence analysis of 
35wk (C.) and 50wk (D.) Sf1+/+:R26R+/DNMaml, Sf1+/Cre:R26R+/DNMaml, 
Sf1+/Cre:R26R+/DNMaml and Sf1+/Cre:R26RDNMaml/DNMaml male mice for Cyp11b1 (red), 












































































































































































































































Figure 3.12: Inhibition of canonical Notch signaling in Sf1 positive cells has 
no effect on the adrenal glands of male mice. A. Histology of adrenals from 
Sf1+/+:R26R+/DNMaml, Sf1+/Cre:R26R+/DNMaml, Sf1+/Cre:R26R+/DNMaml and 
Sf1+/Cre:R26RDNMaml/DNMaml  male mice between 18 and 50wks of age. B. 
Immunofluorescence analysis of adrenals from 50wk Sf1+/+:R26R+/DNMaml, 
Sf1+/Cre:R26R+/DNMaml, Sf1+/Cre:R26R+/DNMaml and Sf1+/Cre:R26RDNMaml/DNMaml  male 








































































































































Figure 3.13: Inhibition of canonical Notch signaling in Sf1 positive cells 
results in abnormalities in the ovary. B. Histology of ovaries from 
Sf1+/+:R26R+/DNMaml, Sf1+/Cre:R26R+/DNMaml, Sf1+/Cre:R26R+/DNMaml and 
Sf1+/Cre:R26RDNMaml/DNMaml  female mice between 4 and 30wks of age. C. 
Immunohistochemistry for Sf1 in ovaries from 9 weeks old Sf1+/+:R26R+/DNMaml 

























































Figure 3.14: Overactivation of Notch signaling in Sf1 positive cells results 
in stochastic adrenal aplasia. A. The urogenital track of Sf1+/+:R26R+/NICD and 
Sf1+/Cre:R26R+/NICD P0 male and female mice, respectively. Adrenal glands (Ad) 
are indicated with yellow arrows. Gonads (Go) are indicated with red arrows. K: 
kidney, Bl: bladder. B. Zoomed in images of the left adrenal glands (Ad) superior 
to the kidney (K) in Sf1+/+:R26R+/NICD and Sf1+/Cre:R26R+/NICD P0 male mice. C. 
Immunofluoresence of Sf1+/+:R26R+/NICD and Sf1+/Cre:R26R+/NICD of P0 female (top 





































































































Mouse Line Primer #1 Primer #2 Primer #3
HesGFP 5'­gcacgacttcttcaagtccgccatgcc­3' 5'­gcggatcttgaagttcaccttgatgcc­3'
Sf1Cre 5'­caatttactgaccgtacac­3' 5'­agctggcccaaatgttgctg­3' n.a.
THCre 5'­gcggtctggcagtaaaaactatc­3' 5'­gtgaaacagcattgctgtcactt­3'
Rosa Tomato/EGFP 5'­ctctgctgcctcctggcttct­3' 5'­cgaggcggatcacaagcaata­3' 5'­tcaatgggcgggggtcgtt­3'
Rosa DNMaml 5'­aaagtcgctctgagttgttat­3' 5'­gcgaagagtttgtcctcaacc­3' 5'­ggagcgggagaaatggatatg­3'
Rosa NICD 5'­taagctgcccagaagactc­3' 5'­gaaagaccgcgaagagtttg­3' 5'­aaagtcgctctgagttgttat­3'
SRY 5'­aagcgccccatgaatgcatt­3' 5'­cgatgaggctgatatttata­3' n.a.
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Antibody Name Species Company Catalog #  Notes
Jagged1 (C­20) Goat  Santa Cruz Sc­6011
JAG1 Rabbit Abcam Ab7771
Dll4 Rabbit Abcam Ab7280
Notch1 (C­20) Goat Santa Cruz Sc­6014
Notch2 (25­255) Rabbit Santa Cruz Sc­5545
Dlk1 Rat N.A. N.A. A generous gift from Charlotte Harken Jensen
Sf1 Rabbit N.A. N.A. A custom polyclonal antibody
TH Mouse Millipore MAB318
PNMT Rabbit Milipore AB110
DAT1 Rat Millipore MAB369
TuJ1 Mouse Covance MMS­435P
Cyp11b1 Rat N.A. N.A. A generous gift from Celso Gomez­Sanchez
20alphaHSD Rabbit N.A. N.A. A generous gift from Yacob Weinstein
Beta­Catenin Mouse BD Biosciences 610154
GFP Rabbit Invitrogen A11122
Beta­Actin Mouse Sigma A­5411
Anti­Goat IRDye Donkey LICOR 926­32214
Anti­Mouse IRDye Goat LICOR 926­32220
Anti­Rabbit IgG HRP Goat Pierce 31462
Anti­Rat Dylight 549 Goat Jackson ImmunoResearch 112­505­044
Anti­Rabbit Dylight 549 Goat Jackson ImmunoResearch 111­506­045
Anti­Goat Dylight 549 Rabbit Jackson ImmunoResearch 305­505­045
Anti­Mouse Dylight 549 Goat Jackson ImmunoResearch 115­485­174
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Chapter 4: Conclusions and Future Directions 
 
 The proper receipt and transmission of molecular signals is essential for 
cellular function during development and homeostasis. Improper cell-cell 
communication can lead to abnormalities in the development of organs [1], failure 
in maintenance of organ homeostasis [2], or even cancer [3]. The evolutionarily 
conserved Notch pathway has been implicated in many of these processes in a 
variety of tissue types [4]. Notch signaling occurs through interactions between 
transmembrane ligands and receptors and culminates in the release of the active 
signaling molecule, the cleaved Notch intracellular domain (NICD) [5]. Therefore, 
canonical Notch signaling requires direct cell-cell contact. However, unlike most 
signaling pathways, no signal amplification occurs in Notch signaling because 
each Notch receptor can only generate a single NICD molecule [6]. These unique 
aspects of Notch pathway activation allow for incredible fine-tuning in the type of 
signals that Notch can receive and transmit. It is not surprising that Notch 
signaling has been implicated in a host a developmental disorders as well as 
cancer [1, 4]. However, Notch signaling has never been considered in the 
adrenal glands, endocrine organs responsible for coordinating the mammalian 
stress response. Understanding the role of Notch signaling in the adrenal glands 
may reveals insights into normal and pathogenic adrenal biology. 
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In Chapter 2 of this thesis, we interrogated the role of Notch signaling in 
adrenocortical cancer. Adrenocortical tumors are common with benign 
adrenocortical adenomas (ACA) present in about 4-7% of the population while 
adrenocortical carcinomas (ACC) present at a much lower frequency (about 1-2 
cases/million/year) but are highly aggressive, deadly neoplasms [7, 8]. We have 
identified an upregulation of the Notch ligand Jagged1 (JAG1) in ACC compared 
to ACA and normal adrenals. An upregulation of the Notch receptors Notch2 and 
Notch3 was also observed and Notch3 expression correlated with JAG1 
expression. Notch target genes Hes1 and Hey1 were also upregulated in ACC. 
Taken together these data suggest an overactivation of canonical Notch 
signaling is occurring in ACC.  
Indeed, we have shown that Jag1 mediates a non-cell autonomous effect 
on cell proliferation in the Y1 mouse ACC cell line. Knockdown of Jag1 in Y1 
cells resulted in a non-cell autonomous reduction in cell proliferation while 
inhibition of all downstream canonical Notch signaling phenocopies the Jag1 
knockdown experiments. Furthermore, JAG1 expression was found to correlate 
with late stage and high grade human ACC, as well as markers of proliferation, 
TOP2A and KI67. These data support a role of Jag1-dependent Notch receptor 
activation in exacerbating the ACC phenotype by augmenting cellular 
proliferation of ACC cells. 
The observation that JAG1 expression correlates with late stage ACC 
suggest that JAG1 may not be involved in initiation of ACC tumorigenesis but 
may function in progression to a more aggressive ACC phenotype. Indeed, a 
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multitude of factors and signaling pathways have been implicated in ACC 
pathogenesis [9]. Constitutive activation of β-catenin, the downstream effector of 
Wnt signaling, has been shown to cause adrenocortical hyperplasia and 
microscopic adenomas [10, 11]. Insulin-like growth 2 (IGF2), a ligand of the IGF 
signaling pathway, is consistently identified at the most upregulated gene in ACC 
compared to ACA and normal adrenals [12, 13]. We have recently published a 
study in which these two factors have been found to synergize in the 
development of adrenocortical tumors in the laboratory mouse [10]. However, a 
lack of bona fide ACC was reported which suggests that overactivation of Wnt 
and IGF pathways are not sufficient to drive adrenocortical carcinogenesis.  
The Notch pathway may be involved in the progression to ACC. The 
status of the Notch signaling pathway has not been interrogated in the tumors 
that developed in the Wnt/IGF study [10]. A comprehensive analysis of Jag1 
expression in these tumors may reveal an upregulation of Jag1 in the more 
histopathologically severe tumors. This observation would confirm that Jag1 
upregulation concomitant with overactivation of the Wnt and IGF pathways is 
required for progression Furthermore, other adrenal tumors models have been 
reported but Jag1 expression has not been considered in any of these models 
[11, 14]. Future analyses may entail interrogation of the status of Jag1 
expression in these mouse adrenal tumor models and consideration if the level of 
Jag1 expression correlates with tumor aggressiveness and/or proliferation. 
In Chapter 3 of this thesis, we examined the function of Notch signaling in 
normal adrenocortical cells during development. Jag1 expression can be 
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detected in the subcapsular region of the adrenal cortex. This zone has 
previously been shown to be involved in adrenocortical homeostasis [2, 15]. 
However, inhibition of canonical Notch signaling in Sf1+ cells had no effect on the 
development or maintenance of the adrenal cortex. These data contrast with the 
role of Notch signaling in ACC. However, the molecular profile of a cancer cell is 
often drastically different than the molecular profile of the normal cell from which 
the cancer is derived [12]. The function of a pathway in cancer does not predict 
the same function of that pathway in the normal cell. Indeed, our analysis of 
Notch in adrenocortical function appears to confirm this supposition.  
Furthermore, overactivation of Notch signaling in Sf1+ cells resulted in 
adrenal aplasia. These results are difficult to interpret due to the lack of 
endogenous Notch activity in normal Sf1+ adrenocortical cells. The Sf1+/Cre 
mouse line employed in these studies is also active as early as E10.5, which 
suggest the adrenal failure can occur at anytime between E10.5 and E18.5 [16]. 
A future study that is far more interesting and biologically relevant would be to 
overactivate canonical Notch signaling and/or overexpress Jag1 in Sf1+ cells of 
the adult adrenal cortex concurrent with stabilization of β-catenin and/or the IGF 
pathway. These experiments would help to elucidate whether Notch pathway 
overactivation can exacerbate adrenocortical tumorigenesis in a molecular 
environment that is already predisposed to the development of benign 
adrenoocortical tumors. It is plausible that overexpression of Jag1 and/or 
constitutive stabilization of Notch signaling in the context of overactivation Wnt  
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and/or IGF signaling may results in progression to bona fide ACC in the 
laboratory mouse. 
Alternatively, in Chapter 3 of this thesis, we instead identified that Notch 
signaling is active in chromaffin cells of the adrenal medulla. The adrenal medulla 
is of distinct ontogeny and function from the adrenal cortex; it is neural crest-
derived and secretes the catecholamine hormones epinephrine and 
norepinephrine whereas the cortex is mesoderm-derived and secretes steroid 
hormones. We identified expression of the canonical Notch target genes Hes1 
and Hes5, ligands Jag1 and Dll4, noncanonica ligand Dlk1, and receptors Notch1 
and Notch2 in adult chromaffin cells. Furthermore, Hes1 and Hes5 expression 
was identified in putative chromaffin progenitors pre- and post- migration into the 
adrenal primordia during medullary development. When canonical Notch 
signaling was inhibited in tyrosine hydroxylase (TH)+ cells (TH is the rate limiting 
enzyme in catecholamine synthesis and is expressed in every adrenal medullary 
chromaffin cell [17]), we observed no changes in the overall histology of 
chromaffin cells but identified an upregulation in TH mRNA and protein. The lack 
of a more prominent phenotype may be a consequence of the mosaic expression 
of the TH+/Cre line employed in this study. A sufficient number of chromaffin 
progenitors may avoid Notch inhibition and develop to mature chromaffin cells. 
Furthermore, during development, a distinct population of cells that are 
Hes1+/TH- was detected in the vicinity of the adrenal primordia. Other studies 
have suggested that some chromaffin progenitors may lack TH expression prior 
to invasion of the adrenal primordia [18]. Therefore, we may not be targeting 
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bona fide chromaffin progenitors cells and thus not affecting development of the 
adrenal medulla. 
Nevertheless, the TH+/Cre line is still active in some TH+ cells of the adult 
adrenal medulla and therefore, Notch inhibition is occurring in a subpopulation of 
adult chromaffin cells in this study. The observation that TH mRNA and protein 
are upregulated suggests a Notch-dependent inhibition of TH expression may be 
occurring in adult chromaffin cells. However, the broad expression of Hes1 and 
the Notch ligands throughout the TH+ adrenal medulla argues against the 
complete suppression of TH expression by Notch signaling. Instead, Notch may 
serve to fine-tune the amount of TH that is expressed in order for the medulla to 
properly respond to different stressors. Future experiments may entail various 
stress paradigms in Notch inhibition mice and measurements of changes of 
catecholamines and/or their metabolites that may occur in this model under 
stressed and unstressed conditions. 
In contrast, when we overactivated Notch signaling in TH+ cells, we 
observed no changes in the overall histology of chromaffin cells except for a 
reduction in phenylethanolamine-N-methyltransferase (PNMT) expression, an 
enzyme required for synthesis of epinephrine and marker of adrenergic 
chromaffin cells [17]. These data suggest that overactivation of Notch signaling 
may reduce the population of adrenergic chromaffin cells. However, only a few 
animals have been analyzed and a much larger sample size is needed to confirm 
this intriguing observation. Furthermore, since the loss of PNMT expression was 
observed in 6wk old animals but was not examined in neonatal animals, a more 
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obvious affect on PNMT expression may be observed in aged animals. 
Measurement of circulating catecholamine hormones and/or their metabolites 
would reveal if there is differences in the amount of epinephrine being secreting 
from the adrenal medulla because the medulla is the primary site if epinephrine 
synthesis and secretion [17, 19].  
Our Notch inhibibition and overactivation studies reveal a differential 
requirement of Notch signaling in regulating the expression of catecholamine-
synthesizing enzymes; reduction in Notch signaling results in TH upregulation 
while overactivation results in PNMT downregulation. These observations seem 
to contradict our observation of Notch signaling throughout the adrenal medulla 
concomitant with TH and PNMT expression. These data suggest that Notch in 
the medulla may be not “all or none” but may be specific to each chromaffin cell-
cell contact. That is to say, too much Notch signaling may reduce PNMT gene 
expression but the “right” amount may promote it. The same type of argument 
could be made for the regulation of TH expression; not enough results in 
upregulation were just the “right” amount maintains steady-state levels.  Indeed, 
the different expression patterns of Hes1 versus Hes5 and Dll4 compared to 
Jag1 seem to suggest that differential Notch ligand-receptor signaling may be 
occurring in subpopulations of chromaffin cells. However, the effect of Notch on 
catecholamine-synthesizing enzymes may also be indirect, mitigated through 
other pathways and/or transcription factors. 
Furthermore, the noncanonical Notch ligand Dlk1, which we detect 
throughout the medulla (as has been reported previously [20]), may play a role in 
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the balance of Notch signaling between chromaffin cells. Dlk1 has been 
suggested to inhibit Notch signaling in a cell-autonomous manner but this not 
been experimentally confirmed as a consequence of direct Dlk1 binding to Notch 
receptors [21]. In our system, Dlk1 may indeed inhibit some Notch signaling in 
chromaffin cells in order to allow for the proper dosage of the Notch signal 
required by an individual chromaffin cells under different conditions. Analysis of 
Dlk1 knockout mice may reveal insights into this putative role. 
Finally, the Notch overactivation studies may have implications in 
pheochromocytoma (PCC), a catecholamine-secreting neoplasm derived from 
the adrenal medulla. Gene expression profiling of PCC identified an upregulation 
of Jag1 and Notch3 in both sporadic and hereditary norepinephrine-secreting 
PCC compared to hereditary and sporadic epinephrine-secreting PCC [22]. 
These data supplement our observation that Notch overactivation reduces PNMT 
expression and suggests that Notch overactivation may promote a 
noradrenergic-like phenotype. Additional studies on a larger cohort of PCC would 
be necessary to confirm this observation. It is possible that overactivation of 
Notch signaling in TH+ cells may even yield PCC in aged animals. In the 
hereditary cancer disorder, von-Hippel Lindau syndrome, an autosomal dominant 
disorder in which the VHL tumor suppressor gene is mutated, PCC develop that 
are norepinephrine-secreting [23]. To interrogate the function of Notch signaling 
in norepinephrine-secreting PCC, one possible avenue of investigation would be 
overactivaiton of Notch signaling in chromaffin cells that are deficient for the VHL 
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gene. It is possible that norepinephrine-secreting PCC may develop under these 
conditions. 
In this thesis we have characterized Notch signaling in adrenocortical 
cancer and in the normal adrenal medulla. These studies illustrate the highly 
context-dependent role of Notch in various systems. While a great deal of work is 
needed to further characterize the precise role of Notch in the medulla, our data 
support a role of Notch signaling in modulation of catecholamine production from 
chromaffin cells. Furthermore, the identification of an upregulation of JAG1 in 
ACC is intriguing but the mechanism of JAG1 upregulation and the complement 
of genes that Notch signaling regulates in ACC still need to be elucidated. 
Targeting Jag1-mediated Notch signaling in late stage ACC may represent a 
novel therapeutic option in the treatment of ACC. This plausibility of this idea is 
highlighted by the existence of a variety of pharmacological methods to inhibit 
Notch signaling in a clinical setting [24].   Further characterization of Notch 
signaling in ACC may open avenues of research that culminate in improved 
treatment for this dismal disease. 
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